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ABSTRACT
SA-4-1BBL AS A MODULATOR OF INNATE, ADAPTIVE, AND REGULATORY
IMMUNITY: IMPLICATIONS FOR CANCER PREVENTION AND TREATMENT

Hampartsoum Barsoumian
April 14, 2016
SA-4-1BBL is a recombinant costimulatory molecule that is active in its soluble
form and has pleiotropic effects on the functions of innate, adaptive, and regulatory
immune cells. We have previously shown that SA-4-1BBL makes CD4+ T conventional
cells (Tconvs) resistant to suppression by CD4+CD25+Foxp3+ T regulatory cells (Tregs).
The mechanistic basis of this observation is the subject of this study. We demonstrate that
Tconvs, but not Tregs, are the direct targets of SA-4-1BBL-mediated evasion of Treg
suppression without contribution from antigen presenting cells (APCs). SA-4-1BBL
engagement with its receptor, 4-1BB, on Tconvs resulted in the production of high levels
of IL-2 cytokine that was necessary and sufficient in overcoming Treg suppression.
Removal of IL-2 from culture supernatant restored Treg suppression and repletion of
Tconv:Treg cocultures with exogenous recombinant IL-2 overcame suppression.
In a series of studies our laboratory demonstrated the therapeutic efficacy of SA4-1BBL as an adjuvant component of subunit cancer vaccines in various preclinical
rodent cancer models. Inasmuch as SA-4-1BBL contains streptavidin (SA) as a foreign
bacterial protein, repeated vaccinations may generate anti-SA antibodies. Such antibodies
may have positive or negative effect on the efficacy of the vaccines. Therefore, a series of
v

studies were conducted to assess the potential impact of SA’s immunogenicity on the
immuno-stimulatory function of SA-4-1BBL molecule. We demonstrated that repeated
treatments with SA-4-1BBL generate both cellular and humoral immune responses
against the SA portion of the molecule. Antibodies against SA neither blocked nor
improved the costimulatory function of SA-4-1BBL on T cells. Importantly, preimmunization with SA-4-1BBL protein alone did not interfere with the therapeutic
efficacy of a subunit vaccine consisting of the human papillomavirs (HPV) E7 tumor
associated antigen (TAA) + SA-4-1BBL in the TC-1 cervical cancer tumor model.
Surprisingly, pretreatment with SA-4-1BBL alone conferred protection regardless of the
type of tumor tested.
The robust anti-tumor function of SA-4-1BBL involved a communication bridge
between CD4 and NK cells without significant contribution from CD8 cells or B cells.
NK cells were found to be critical to the observed tumor suppression and required CD4+
T cell help for protective efficacy at both priming and effector stages. Depletion of either
NK or CD4 cells negated SA-4-1BBL’s anti-tumor protection. Moreover, the tumor
suppressive effect of SA-4-1BBL was shown to be a bona fide property of this molecule,
as immunizing mice with an agonistic antibody to 4-1BB receptor did not confer any
protection against TC-1 tumors.
The significance of understating the mechanisms underlying SA-4-1BBL’s mode
of action provides new tools in the evolving field of cancer immunotherapy and
prevention. The implications also extend to transplantation settings as well as infectious
diseases where tipping the balance between Tregs and T effector cells (Teffs) plays a
critical role in achieving desired outcomes.

vi

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION ....................................................................................... 1
Costimulation as a critical signal for productive T cell responses .................................. 1
TNFR family members in costimulation ......................................................................... 3
4-1BB costimulation and signaling background ............................................................. 5
4-1BB in Cancer Vaccines .............................................................................................. 7
SA-4-1BBL as a potent adjuvant .................................................................................... 9
SA-4-1BBL adjuvant effect on adaptive immunity ................................................... 10
SA-4-1BBL adjuvant effect on innate immunity ...................................................... 11
SA-4-1BBL’s role in regulatory immunity ............................................................... 12
CHAPTER 2: SA-4-1BBL LIBERATES CONVENTIONAL T CELLS FROM
NATURAL T REGULATORY CELLS SUPPRESSION VIA IL-2 ............................... 14
Introduction ................................................................................................................... 14
Materials and Methods .................................................................................................. 15
Mice and reagents ...................................................................................................... 15
Cell sorting ................................................................................................................ 16
Ex-vivo expansion of Tregs ....................................................................................... 16
Suppression assays with and without APCs .............................................................. 16
Cytometric bead array ............................................................................................... 17
RT-PCR for IL-2 expression ..................................................................................... 17
Removal of SA-4-1BBL and IL-2 from Tconv culture supernatant ......................... 18
Statistical analysis...................................................................................................... 19
Results ........................................................................................................................... 19
APCs do not contribute to SA-4-1BBL-mediated evasion of Treg suppression ....... 19
TGF- and IFN do not contribute to SA-4-1BBL-mediated evasion from Treg
suppression ................................................................................................................ 20
vii

IL-2 is the major cytokine produced in the supernatant of Tconv:Treg cocultures
costimulated with SA-4-1BBL .................................................................................. 21
IL-2 is necessary and sufficient for Tconvs to overcome Treg suppression ............. 22
IL-2-mediated Tconvs evasion of Tregs suppression is independent of Tregs
proliferative state ....................................................................................................... 23
Discussion ..................................................................................................................... 24
CHAPTER 3: SA-4-1BBL AS AN IMMUNE ADJUVANT FOR THE GENERATION
OF PROTECTIVE INNATE AND ADAPTIVE IMMUNE RESPONSES AGAINST
TUMORS .......................................................................................................................... 29
Introduction ................................................................................................................... 29
Materials and Methods .................................................................................................. 31
Mice ........................................................................................................................... 31
Antibodies and Reagents ........................................................................................... 31
Immunization strategy and tumor challenge ............................................................. 32
Enzyme-linked immunosorbent assay (ELISA) for serum antibodies and subtyping32
Adoptive serum transfer ............................................................................................ 33
Anti-CD3 proliferation assay..................................................................................... 33
Flow cytometry and phenotyping .............................................................................. 33
Statistics ..................................................................................................................... 34
Results ........................................................................................................................... 34
Streptavidin portion of SA-4-1BBL is immunogenic................................................ 34
Anti-SA Abs do not negatively impact the costimulatory function of SA-4-1BBL in
vitro and in vivo ......................................................................................................... 35
Pretreatment with SA-4-1BBL generates a prolonged window of immune responses
against TC-1 tumor .................................................................................................... 36
SA-4-1BBL generates long-term immune memory against TC-1............................. 37
The protective effect of pretreatment with SA-4-1BBL is tumor-type independent . 37
Anti-SA Abs do not play a role in the protective effect of pretreatment with SA-41BBL against TC-1 tumor ......................................................................................... 38
Protective effect of SA-4-1BBL against tumor involves a cross-talk between NK and
CD4+ T cells .............................................................................................................. 38
CD4 cells should recognize SA for optimal anti-tumor protectivity ......................... 39
viii

The anti-tumor effect of SA-4-1BBL is a unique property of this molecule and is not
achieved using agonistic Ab to the receptor .............................................................. 40
Discussion ..................................................................................................................... 42
FIGURES .......................................................................................................................... 48
REFERENCES ................................................................................................................. 88
CURRICULUM VITAE ................................................................................................... 95

ix

LIST OF FIGURES
FIGURE

PAGE

1. Costimulation by SA-4-1BBL overcomes suppression of Tconvs by Tregs
independent of APCs………………………………………………………..48
2. Costimulation by SA-4-1BBL overcomes suppression of Tregs to Tconvs in
absence of APCs…………………………………………………………….49
3. TGF-β cytokine is not involved in Tconv evasion of Treg suppression…….50
4. Cell surface-bound TGF-β is not involved in Tconv evasion of Treg
suppression………………………………………………………………….51
5. IFN-γ cytokine is not involved in Tconv evasion of Treg suppression……..52
6. IL-2 is a predominant cytokine upregulated in Tconv and Tregs cocultures
costimulated with SA-4-1BBL……………………………………………...53
7. IL-2 is the predominant cytokine upregulated in Tconv and Tregs cocultures
costimulated with SA-4-1BBL without APCs……………………………...54
8. RT-PCR ∆∆CT values for relative IL-2 mRNA expression………………..55
9. Removal of SA-4-1BBL from Tconv culture supernatants………………...56
10. Removal of IL-2 from Tconv culture supernatants…………………………57
11. SA-4-1BBL costimulation-mediated IL-2 production by Tconvs is both necessary
and sufficient in overcoming Treg suppression…………………………….58
12. Tconvs proliferate to a higher extent upon SA-4-1BBL stimulation as compared
to Tregs……………………………………………………………………..59
13. IL-2-mediated Tconvs evasion of Tregs suppression is independent of Tregs
proliferative state…………………………………………………………...60
14. Schematic time line to study SA-4-1BBL’s immunogenicity……………....61
15. Anti-SA antibodies generated in vivo upon SA-4-1BBL immunization……62
x

16. Subtyping serum ELISA for pre-immunization group on days 21 and 90…63
17. SA is immunogenic and drives the proliferation of T cells in vitro………..64
18. Anti-SA antibodies generated in vivo do not help the in vitro proliferative function
of SA-4-1BBL molecule…………………………………………………...65
19. Pre-immunization with SA-4-1BBL does not alter the post-tumor vaccination
outcome, but scores 100% survival against TC-1 tumors…………………66
20. Time-course pre-immunization studies with 1 shot SA-4-1BBL against
TC-1……………………………………………………………………......67
21. Time-course pre-immunization studies with 2 shots SA-4-1BBL against
TC-1…………………………………………………………………….......68
22. Time-course pre-immunization studies continuation with 2 shots SA-4-1BBL
against TC-1………………………………………………………………..69
23. SA-4-1BBL establishes significant long-term immune memory against
TC-1………………………………………………………………………..70
24. SA-4-1BBL primarily generates long-term CD4 effector memory………..71
25. SA-4-1BBL rejects tumors in a non-specific fashion……………………...72
26. Anti-SA humoral immune response did not contribute to the SA-4-1-BBLmediated rejection of tumors……………………………………………….73
27. Depletion of NK cells negates SA-4-1BBL’s protective effect……………74
28. Depletion of CD4 cells but not CD8 cells negates SA-4-1BBL’s protective
effect………………………………………………………………………..75
29. CD4 cells are required during effector phase after TC-1 challenge………..76
30. B cells and antibodies are not involved in SA-4-1BBL-mediated tumor
protection…………………………………………………………………...77
31. SA-4-1BBL immunization is ineffective against TC-1 in 4C mice………...78
32. 4C splenocytes stimulated with SA have compromised proliferation………79
33. SA-4-1BBL immunization is capable of generating anti-SA antibodies in 4C
mice…………………………………………………………………………80

xi

34. Subtyping ELISA at tumor endpoints for 4C mice pre-immunized twice with SA4-1BBL…………………………………………………………………….81
35. SA-4-1BBL vs. SA+3H3: SA-4-1BBL as a bona fide novel immunomodulatory
molecule…………………………………………………………………….82
36. Immunization with 3H3 reduces NK cell percentages in spleen lymphocyte
population…………………………………………………………………..83
37. Immunization with 3H3 reduces NK absolute cell numbers in spleen lymphocyte
population…………………………………………………………………..84
38. Immunization with 3H3 reduces NK cell percentages in draining lymph nodes’
lymphocyte population……………………………………………………...85
39. Immunization with SA+3H3 vs. SA-4-1BBL absolute cell numbers profile in
draining lymph nodes………………………………………………………86
40. SA+ 3H3 immunization shuts down antibody production…………………87

xii

CHAPTER 1: INTRODUCTION

Costimulation as a critical signal for productive T cell responses
T cells are the critical cell type in adaptive immunity. T cells require 3 standard
signals for activation, proliferation, acquisition of effector function, and establishment of
long-term memory. Signal 1 is usually provided through T cell receptor (TCR)
interacting with Major Histocompatibility Complex (MHC) class I or II molecules on
antigen presenting cells (APCs) loaded with processed antigens. Costimulation provides
signal 2, while soluble factors and cytokines constitute signal 3. All signals together
decide on the fate and differentiation of the T cell in concern (1). CD8+ T cells for
example interact with MHC-I during viral infections or in the presence of intracellular
pathogens and acquire effector functions capable of clearing the infection of concern.
CD4+ T cells on the other hand interact with MHC-II molecules and convert from their T
helper Th0 state into either Th1, Th2, Th17, or CD4+CD25+Foxp3+ T regulatory cells
(Tregs) , based on the antigen and type of costimulation engaged (Illustration 1). More
importantly, the lack of costimulation leads to T cell anergy and unresponsiveness
followed by cell death and inefficient tumor or infection clearance.
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Illustration 1. Guarner et al. Nature Clinical Practice Gastroenterology &
Hepatology (2006) 3, 275-284.
Costimulatory molecules in general are categorized into two wider families:
CD28 and tumor necrosis factor receptor (TNFR) superfamily. CD28 for example is
constitutively expressed on T cells and interacts with B7 molecules on APCs to drive
activation of T cells. CD28 action is usually maintained under control by its competitor
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also expressed on T cells and
delivers inhibitory signals when interacting with B7 at higher affinity (2). TNFR family
members on the other hand, such as 4-1BB, OX40, and CD27 (Illustration 2), are
inducibly expressed on activated T cells (CD4+ and CD8+), Tregs, NK cells, mast cells,
and neutrophils (3). The inducible expression on antigen-experienced T cells is
advantageous for the expansion of antigen-specific immune responses in therapeutic
settings and provides a better on/off switch.

2

APC

T cell

Illustration 2. Michael Croft, Nature Reviews Immunology (2003) 3. 609-620.

TNFR family members in costimulation
There are 27 TNF-ligands identified so far with biological functions. Ligand/receptor
pairs with costimulatory signaling capacity include CD40L (CD154)/CD40, CD70/CD27,
4-1BBL/4-1BB (CD137), OX40L/OX40 (CD 134), GITRL/ GITR (CD 357), and
HVEMLs/ HVEM (CD 270), that have showed promise as therapeutic modulators of T
cell immunity (4).
CD40L/CD40: CD40L expression has been identified on activated B cells, epithelial
cells, endothelial cells, platelets, smooth muscle cells, and DCs. Expression of its
receptor CD40 is found on B-cells, monocytes, macrophages, platelets, DCs, eosinophils,
and activated CD8+ T cells (4). The main function of CD40L/CD40 is to activate and
3

“license” DCs to prime effective cytotoxic CD8+ T-cell responses. In its absence
“unlicensed” DCs induce T-cell anergy or T-cell deletion and generate regulatory T cells
(5, 6).
CD70/CD27: The expression of CD70 is restricted to activated T and B lymphocytes and
mature DCs. CD27 is a type I transmembrane receptor expressed on naive T cells, mature
T cells, memory B cells, and NK cells (4). The key biological function of CD70 is to
prime CD4+ and CD8+ T cell responses and enhance T-cell survival and effector
functions. CD70/CD27 signaling promotes the development of CD4+ T cells that are able
to produce Th1 and Th2 cytokines (7).
OX40L/OX40: OX40 is majorly expressed by activated CD4+ and CD8+ T cells, NK
cells, NKT cells, and neutrophils. OX40L is primarily expressed by APCs such as DCs,
B-cells, and macrophages. OX40 provides a co-stimulatory signal to TCR-stimulated T
cells and enhances clonal expansion, proinflammatory cytokine production, and
generation of memory CD4 T cells. Furthermore, OX40 promotes CD8 T cells survival
and expansion directly or indirectly via the induction of CD4 T-helper responses (8).
GITRL/GITR: GITR is expressed at low levels on resting CD4+ and CD8+ T cells, DCs,
monocytes, and NK cells. GITR ligand (GITRL) is highly expressed on activated APCs
and endothelial cells (ECs), and it promotes leukocyte adhesion and transmigration (9).
Moreover, GITR ligation has been shown to break self-tolerance and abrogate T-cell
suppression by Tregs, which could be utilized as a target for cancer immunotherapy (10).
HVEMLs/HVEM: The Herpesvirus entry mediator (HVEM) expression is in fact
opposite to 4-1BB, OX40, and GITR expression patterns. HVEM is highly expressed on
naive and memory B cells as well as resting T cells, but down regulates upon B and T
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cell activation. There are four ligands for HVEM: CD160 (a member of the Ig
superfamily); B- and T-lymphocyte attenuator (BTLA); LIGHT; and lymphotoxin-alpha.
Interaction of CD160 and BTLA with HVEM inhibits B and T cell activation, while
interaction of LIGHT or lymphotoxin-alpha with HVEM triggers T and B cell activation
and APC maturation and differentiation (11).

4-1BB costimulation and signaling background
4-1BB, also known as CD137/TNFSF9, is a member of TNFR superfamily (12).
It is a costimulatory molecule that is upregulated on the surface of lymphoid cells such as
T cells, B cells, and NK cells when activated and non-lymphoid cells such as dendritic
cells (DCs), macrophages, neutrophils, and malignant tumor endothelial cells (13). Upon
4-1BB receptor clustering, a heterotrimer is formed consisting of TNF-receptor
associated factors (TRAFs) where two molecules of TRAF2 combine with one molecule
of TRAF1. TRAF2 initiates a signaling cascade of mitogen-activated protein (MAP)
kinases and NF-κB activation, which in turn leads to the production of more TRAF1 that
sustains the effect of 4-1BB costimulation. TRAF1 favors extracellular signal-regulated
kinase (ERK) pathways (Illustration 3). The end result is the expansion and survival of T
cells, acquisition of effector functions, and establishment of long-term memory (14, 15).
Key cytokines produced also include TNF-α, IL-2, IL-12, and IFN-γ.

5

Illustration 3. Chao Wang, Tania H. Watts. Cytokine & Growth Factor Reviews (2012)
23, 245–254.
More recently 4-1BB costimulation has been shown to reduce T cell exhaustion in
ex vivo settings where there is persistent antigen exposure. The authors in the study used
genetically engineered T cells that express chimeric antigen receptors (CARs) capable of
recognizing specific antigens and activating T cells independent of MHCs. Contrary to 41BB, CD28 costimulation in the CAR model has been shown to enhance exhaustion (16).
In a transplanted melanoma model, Curran et al. have shown that mice treated with anti4-1BB antibodies generate novel forms of CD4+ killer and CD8+ killer tumor infiltrating
T cells characterized by the expression of killer-cell lectin like receptor G1 (KLRG1)
and the transcription factor Eomesodermin (Eomes) independent of the T-box
transcription factor (T-bet) expression. These cells were shown to produce granzymes
capable of killing melanoma cells. In addition to that, amongst the members of TNFR
family agonists, only 4-1BB signaling has generated the KLRG1+Eomes+ killer
phenotype, while anti-OX40, anti-GITR, and anti-CD27 could not (17).
6

It is important here to also shed light on the regulatory aspects of 4-1BB signaling
as it plays a double edged sword by generating and expanding effector immunity as well
as expanding and promoting Treg functions and redirecting T cell polarization. In mice
for example, 4-1BB is constitutively expressed on Tregs and can respond to 4-1BBL +
IL-2 + TGF-β stimuli to induce their proliferation. The duality of 4-1BB function seems
to be at least partially controlled by Galectin-9, a member of the β-galactoside–binding
family of lectins (18). Upon addition of anti-4-1BB antibody (clone 3H3), Gal-9 binds to
4-1BB on the cell surface without competing with the binding sites of the ligand nor 3H3.
Gal-9 binding is demonstrated to be required for the ability of 4-1BB signaling to
suppress experimental autoimmune encephalomyelitis (EAE) and allergic asthma in vivo
(18). In another study, 4-1BB ligand was shown to play a regulatory role in T cells that
are weakly activated under suboptimal conditions below the threshold of 4-1BB
expression and activation. Once the activation threshold was met, cell intrinsic 4-1BB
was shown to downregulate the expression of 4-1BBL by endocytosis and internalization
(19). This balance between the ligand and the receptor is necessary for maintaining
immune system homeostasis.

4-1BB in Cancer Vaccines
Cancer vaccines usually consist of two major categories:
Prophylactic/preventative such as Gardasil® and Cervarix® against Human
Papillomavirus (HPV) 16 and 18, or therapeutic such as the dendritic cell based vaccine
(Sipuleucel-T) approved by the FDA in the USA on 2010. The down side of DC vaccines
is that they are relatively expensive, need to be subject customized, and are technically
challenging to produce. Subunit vaccines consisting of tumor associated or specific
7

antigens and immune-adjuvants, are more economically feasible and present as effective
alternatives to cell-based vaccines with ease of production and marketing. The culprit in
the subunit vaccines is that the immunogenicity of most antigens is low, most of them
being self antigens, as well as the lack of potent and safe vaccine adjuvants capable of
overcoming tumor immune evasion mechanisms. As such, in the absence of predefined
tumor specific antigens and alongside conventional chemotherapy, scientists have started
incorporating alternative immune modulators in clinical cancer therapies, such as the use
of monoclonal antibodies targeted towards tumors and/or cells of the immune system.
Some of the clinically approved candidates include i) the monoclonal antibody Herceptin
(Trastuzumab) directed towards breast cancer cells expressing the human epidermal
growth factor receptor 2 (Her2) protein (20). ii) Ipilimumab, an anti-CTLA antibody,
which blocks the action of Tregs giving more room for Teffs and NK cells to carry out
their killer functions (21). iii) Antibodies blocking the programmed death receptor-1 (PD1) that is usually expressed by activated lymphocytes and delivers an inhibitory signal
when associated with its ligand expressed by APCs as well as tumors (22). iv) Agonistic
antibodies to 4-1BB costimulatory receptor, especially picked from the tumor necrosis
factor superfamily due to its promising pre-clinical and clinical outcomes in fighting
tumors and activating a wide array of effector immune cells.
The major drawback of anti-4-1BB antibodies is the high level of associated
toxicity as reported by several studies in rodents and humans (15). Toxicity profiles are
usually characterized by non-specific activation of immunity resulting in systemic
inflammation, splenomegaly, lymphadenopathy, increased liver enzymes AST/ALT, as
well as hepatitis. The observed toxicity is shown to be independent of FcγR or
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complement system activation as inflammation was persistent in FcγR−/− and
complement C1q-/- or C3-/- knockout mice (23). Upregulation of non-specific CD4+ and
CD8+ T cells was noted upon immunizing naïve C57BL/6 mice with anti-4-1BB antibody
clone 3H3 accompanied with high levels of IFN-γ and TNF-α production. Higher doses
of 3H3 also abrogated T helper cell dependent humoral immunity, caused more
hepatomegaly, as well as anemia and disturbance in bone marrow’s cellular compartment
(24).

SA-4-1BBL as a potent adjuvant
Taking into account the various toxic facets of agonistic 4-1BB antibody
treatments and the fact that naturally occurring 4-1BBL is inactive in its soluble form
unless bound to a cell surface membrane, our lab has generated and produced a novel
soluble form of 4-1BBL adjuvant by fusing the extracellular domain of murine 4-1BBL
to the C-terminus of a modified core streptavidin (SA). SA forms stable tetramers and
oligomers which is important to cluster the 4-1BB receptors on corresponding cells and
enhance signal transduction (Illustration 4). Side by side comparison studies between
soluble SA-4-1BBL and 3H3 have shown SA-4-1BBL to be more potent activator than
3H3 while lacking the antibody associated toxicity (23). Our lab has conducted a series of
extensive studies demonstrating the in vitro and in vivo pleiotropic functions of SA-41BBL on adaptive, innate, and regulatory immune cells.

9

Illustration 4. SA-4-1BBL structural representation. Shirwan’s Lab, 2016.
SA-4-1BBL adjuvant effect on adaptive immunity
In our attempt to develop subunit based therapeutic cancer vaccines using defined
TAAs, SA-4-1BBL was shown to act on CD4+ as well as CD8+ T cells to fulfill its potent
adjuvant role in the designed vaccine formulations. Depletion of CD4+ T cells 1 day prior
tumor inoculation in two transplantable models (TC-1 cervical cancer expressing Human
Papillomavirus antigen E7; and 3LL lung carcinoma overexpressing the self antigen
survivin) was shown to significantly reduce the therapeutic vaccine efficacy administered
6 days later from tumor challenge (25). Upon rechallenge of tumor free mice, long term
immunological memory was also lost in the absence SA-4-1BBL effect on CD4+ T cells.
In another study using survivin + SA-4-1BBL vaccine in 3LL model, 100% of tumor
eradication was achieved in a prime-boost vaccination strategy. Depletion of CD8+ T
cells producing IFN-γ 1 day prior vaccinations completely compromised therapeutic
efficacy while depletion of NK cells had moderate yet noticeable effect on tumor growth.
NK cells isolated from immunized mice showed improved killing against YAC-1 target
cells in vitro (26).
10

SA-4-1BBL adjuvant effect on innate immunity
Switching gears towards innate immunity, SA-4-1BBL’s direct or indirect effect
on NK cells has been shown to be indispensable for HPV-16 E7 recombinant proteinbased therapeutic vaccine in the TC-1 murine tumor model. Eradication of established
tumors was mainly dependent on 4-1BB signaling as C57BL/6.4-1BB knockout
(C57BL/6.4-1BB−/−) mice failed to clear the tumors and expired accordingly (27).
Activated NK cells have been shown in the literature to express 4-1BB receptor
themselves and are involved in the eradication of P815 mastocytoma in vivo although
they lack the in vitro lysis function upon stimulation with anti-4-1BB monoclonal
antibody, suggesting an immuno-regulatory role of NK cells in this case as compared to
direct killing and effector functions (28). NK cells isolated from human peripheral blood,
activated with IL-2/IL-15 cytokines for 48 hours to upregulate 4-1BB, and incubated with
the MCF-7 human breast cancer cell line overexpressing 4-1BBL for additional 12 hours,
have been shown to upregulate perforin, granzyme B, and FasL genes without enhancing
cellular degranulation nor IFN-γ production upon engagement of 4-1BB with 4-1BBL on
MCF-7 cells (29).
Dendritic cells (DCs) of the innate immune system on the other hand, produce a
variety of cytokines such as TNF-α, IL-6, and IL-12 upon 4-1BB stimulation (30, 31).
SA-4-1BBL not only provides robust immune costimulatory activity in DCs in
therapeutic cancer vaccines but also contributes to the delivery of TAAs conjugated
through biotin to the streptavidin portion of the molecule (32). DCs in turn engulf the SA4-1BBL-TAA conjugate and enhance antigen presentation to T cells. TC-1 or 3LL tumor
bearing mice showed significant improvement in survival upon administering SA-4-
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1BBL-TAA conjugate vaccine on day 6 post-tumor challenge versus administering SA-41BBL + TAA without conjugation. The therapeutic efficacy of the vaccine was
associated with higher tumor infiltrating CD8+ T cells to Tregs ratio (32).
Another study conducted in our lab has recently aimed at simultaneous
stimulation of innate and adaptive immunity in fighting tumors using a combination of
the Toll-like receptor 4 (TLR4) agonist called monophosphoryl lipid A (MPL) plus SA-41BBL. One vaccination with the combination of both adjuvants and HPV E7 protein as
TAA resulted in 100% survival in murine TC-1 model. Vaccine formulation containing
SA-4-1BBL had better efficacy (~80%) than formulation with MPL alone (~50%) (33).
SA-4-1BBL’s role in regulatory immunity
SA-4-1BBL has a major impact on regulatory immunity. SA-4-1BBL drives the
proliferation of activated Tregs when combined with the cytokine IL-2 while maintaining
Tregs’ suppressive function (34). Tregs constitutively express the IL-2 and 4-1BB
receptors and SA-4-1BBL costimulation further upregulates the expression of both
receptors. This regulatory aspect of SA-4-1BBL was shown to overcome autoimmune
diseases and prevent graft rejection (34). On the other hand, we showed that SA-4-1BBL
without exogenous IL-2 blocks the conversion of conventional CD4+ T cells into induced
Tregs through the production of IFN-γ (35). One of the important mechanisms by which
tumors evade suppression is the induction of iTregs in the tumor microenvironment and
SA-4-1BBL has the ability to block the accumulation of iTregs even in the presence of
tumor antigens and TGF-β pressure. In the process of exploring the effects of SA-41BBL on Tregs, we have observed that Teffs themselves become resistant and refractory
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to suppression by Tregs (34, 36), the mechanism of which is yet unknown and will be
elucidated in the subsequent chapter of this dissertation.
In summary, 4-1BB signaling has pleiotropic effects in modulating the immune
system by acting on all 3 branches: innate, adaptive, and regulatory immunity. These
effects are content- and model- dependent and need to be carefully considered when
exploiting 4-1BB signaling for the generation of desired immune responses for
therapeutic purposes.
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CHAPTER 2: SA-4-1BBL LIBERATES CONVENTIONAL T CELLS FROM
NATURAL T REGULATORY CELLS SUPPRESSION VIA IL-2
Introduction
CD4+CD25+Foxp3+ Tregs comprise a distinct and important cell type that confers
peripheral tolerance. Deficiencies in Tregs or their regulatory function are associated with
severe autoimmunity in rodents and humans. Their presence or absence has high impact
in transplantation as well as tumor settings. They can mediate graft survival, but can also
abrogate effector T cells from carrying their killing function in tumor microenvironments
(37). Subtypes of Tregs include naturally occurring thymic Tregs (nTregs) that are
CD4+CD25+Foxp3+, and induced Tregs (iTregs) that are CD4+ Foxp3- but convert into
Foxp3+ upon induction in the periphery. Other subtypes include Tr1 and Th3 iTregs that
are Foxp3- but are specialized in IL-10 and TGF-β production (38). Although 4-1BB
receptor is constitutively expressed on Tregs in mice, our lab has previously shown that
in Teff:Treg co-culture experiments, SA-4-1BBL drives the proliferation of Teffs without
altering the suppressive functions of Tregs. Tregs pre-incubated with SA-4-1BBL prior
addition to suppression assays did not cease their suppressive function (34). Moreover,
cultures with Tregs sorted from C57BL/6. 4-1BB-/- mice and incubated with sorted Teffs
from wild type C57BL/6 mice in the presence of SA-4-1BBL showed high proliferation
of Teffs proving that evasion of suppression is not due to direct engagement of SA-41BBL with its receptor on Tregs (36). Combining our
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observations together, we hereby shifted our focus to study the direct mode of action of
SA-4-1BBL on conventional T cells (Tconvs) and the mechanism(s) underlying the
escape from suppression.

Materials and Methods
Mice and reagents
Transgenic C57BL/6.Foxp3GFP and wild type C57BL/6 mice were purchased from The
Jackson Laboratory. C57BL/6.Foxp3hCD2 mice (39) and 4-1BB knockout mice (40) were
bred and cared for in University of Louisville’s SPF-free vivarium in accordance with
NIH guidelines. All animal procedures were approved by the University of Louisville’s
Institutional Animal Care and Use Committee. Antibodies used include anti-CD3
agonistic Ab (clone 145-2C11, BD Pharmingen, Cat# 553058), anti-TGF-β (1,2,3)
neutralizing Ab (clone 1D11, homemade), anti-IFN-γ blocking Ab (clone XMG 1.2,
homemade), and anti-IL-2 neutralizing Ab (clone S4B6, BD Pharmingen, Cat# 554375).
Fluorescein-conjugated Abs to various cell surface markers were obtained commercially:
anti-CD4-APC (BD Pharmingen, 553051); anti-CD25-PE (BD Pharmingen, 553866);
anti-CD25-PE-Cy7 (eBioscience, 25-0251-82); anti-hCD2-PE (BioLegend, 300208).
Where indicated Tconvs or Tregs were stained with 2.5µM CFSE (Invitrogen, C1157).
CTLL-2 cell line was obtained from ATCC (TIB-214). Human IL-2, SA-4-1BBL, and
SA proteins were produced in our lab according to standard protocols as previously
reported (34, 41, 42).
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Cell sorting
Both Tconvs and Tregs were sorted from splenocytes of naive C57BL/6.Foxp3GFP mice
using BD FACSAria by gating on CD4+ CD25- GFP- cells to collect Tconvs and on CD4+
CD25+ GFP+ population to collect Tregs. Tconvs from WT C57BL/6 or Tregs from
C57BL/6.Foxp3hCD2 mice were sorted by gating on CD4+ CD25- to collect Tconvs and
CD4+ CD25+ to collect Tregs. Sorted populations purity was ≥ 99%.

Ex-vivo expansion of Tregs
In select experiments, Tregs were expanded using our previously described protocol (34).
Briefly, 1 x 105 to 5 x 105 sorted Tregs were cultured in a 6 well plate in addition to 1 x
106 irradiated C57BL/6 splenocytes (2000 cGy); anti-CD3 antibody (0.5 µg/ml); SA-41BBL (1 µg/ml); IL-2 cytokine (25 IU/ml). Cells were cultured for 4 days at 37oC, 5%
CO2 after which 1 ml of culture media was displaced with 1 ml fresh MLR media and
supplemented with IL-2 (25 IU/ml). On day 7, cells were collected, centrifuged, washed
and resuspended in fresh MLR media for additional 3 days with IL-2 only (25 IU/ml).
On day 10, cells were washed and rested without IL-2 for two to three days (while
checking viability) prior addition to suppression assays. Expanded Tregs maintain their
Foxp3 expression as tested by flow cytometry (data not shown) and retain their
suppressive functionality.

Suppression assays with and without APCs
Freshly sorted Tconvs (2.5 x 104) were cocultured in 96-well U-bottom plates with
freshly sorted or expanded Tregs (2.5 x 104) plus irradiated naive C57BL/6 splenocytes
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as source of APCs (1 x 105 , 2000 cGy). Cultures were supplemented with anti-CD3 Ab
(0.5 µg/ml), SA-4-1BBL (1 µg/ml), and IL-2 (3 IU/ml) where indicated. In absence of
APCs, Tconvs and Tregs were cultured with plate bound anti-CD3 (5 µg/ml), while
maintaining the rest of the conditions constant. Coculture plates were incubated for 48 h
(37o C, 5% CO2) and pulsed with 1 μCi/well of [3H]-thymidine (PerkinElmer, Cat#
NET027X001MC) for an additional 16 h. Plates were harvested using Tomtec cell
harvester and counts per minute (CPMs) were recorded using Wallac Betaplate liquid
scintillation counter as a measure of cell proliferation.
Cytometric bead array
Th1/Th2/Th17 panel of cytokine beads (BD Biosciences, Cat# 560485) were used to
measure IL-2, IL-4, IL-6, IFN-γ, TNF-α, and IL-17a levels in cell culture supernatants
following manufacturer's instructions. Concentrations of the various cytokines were
calculated against a standard that runs from 0-5000 pg/ml.

RT-PCR for IL-2 expression
Tconvs and Tregs were sorted from splenocytes of naive C57BL/6.Foxp3GFP mice using
BD FACSAria by gating on CD4+ CD25- GFP- cells to collect Tconvs and on CD4+
CD25+ GFP+ population to collect Tregs. Cocultures were stimulated with SA-4-1BBL (1
µg/ml) and plate-bound anti-CD3 Ab (5 µg/ml). Cultures were harvested for total RNA
isolation 24 and 48 hours post-stimulation. RNA was converted into cDNA and used for
real-time PCR amplification using primers for housekeeping gene glyceraldehyde 3phosphate dehydrogenase (GAPDH) and IL-2. Primer sequences (GenScript) were as
follows: IL-2 forward 5’-TGA GCA GGA TGG AGA ATT ACA GG-3’, reverse 5’-GTC
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CAA GTT CAT CTT CTA GGC AC-3’; GAPDH forward 5’-CCA TCA CCA TCT TCC
AGG AGC GAG-3’, reverse 5’-CAC AGT CTT CTG GGT GGC AGT GAT-3’. DeltaDelta CT values were calculated and normalized to GAPDH.

Removal of SA-4-1BBL and IL-2 from Tconv culture supernatant
Supernatants were generated from 96 well cultures of (Tconvs + 5 µg/ml plate
bound anti-CD3 + 1 µg/ml SA-4-1BBL) incubated for 48 hours at 37o C, 5% CO2. Taking
advantage of the 6xHis tag engineered into the SA-4-1BBL molecule, culture
supernatants were incubated with CuSO4-charged sepharose beads for 15 minutes at
room temperature followed by centrifugation and aspiration of the SA-4-1BBL-cleaned
supernatant.
IL-2 was removed by incubating supernatants with anti-IL-2 neutralizing antibody
(20µg/ml, clone S4B6) to form complexes at 37o C for 15-30 minutes. Ab/IL-2
complexes were then removed by incubating with Immobilized Protein G high affinity
beads (Thermo Scientific, Cat# 20398). IL-2-cleaned supernatant was tested on CTLL-2
cells that require IL-2 cytokine as a limiting factor for their growth. CTLL-2 cells were
plated in U-bottom 96 well plates (5000 cells/50µl + 50µl supernatant cleaned from SA4-1BBL only as positive control, or cleaned from SA-4-1BBL and IL-2). Cultures were
incubated for 28 hours total at 37o C, 5% CO2 with addition of [3H]-thymidine for the last
8 hours. Cells were harvested using Tomtec cell harvester and proliferation of CTLL-2
cells was quantified.
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Statistical analysis
Each data point represents the mean ± SEM of triplicate wells unless otherwise stated.
The statistical significance between data points was estimated with two-tailed Student’s t
test using GraphPad software. A p value ≤ 0.05 was considered to be statistically
significant.

Results
APCs do not contribute to SA-4-1BBL-mediated evasion of Treg suppression
In previously published studies, we have demonstrated that SA-4-1BBL
costimulation allows Tconvs to overcome Treg suppression (36). These studies were
conducted using Tregs and Tconvs cocultured with APCs from C57BL/6 wild type mice.
The 4-1BB receptor is expressed on a subpopulation of DCs and stimulation via this
receptor results in the secretion of various cytokines, such as IL-6, IL-12, and TNF-α (30,
31). To assess the potential contribution of signaling in APCs to the observed Tconv
evasion of Treg suppression, suppression assays were performed with irradiated
splenocytes from wild type as well as 4-1BB KO mice. SA-4-1BBL overcame the
suppression of sorted Tconvs cultured by Tregs. More importantly, Tconvs cocultured
with 41BB-/- APCs showed robust proliferation responses when costimulated with SA-41BBL in the absence or presence of Tregs (Fig. 1). These responses were comparable to
those generated with wild type APCs.
To further confirm that APCs do not play a role in the Tconv evasion of Treg
suppression, the coculture studies were performed in the absence of APCs. Stimulation
of Tconvs with plate bound anti-CD3 Ab alone under these culture conditions did not
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generate a significant proliferative response (Fig. 2). However, costimulation with SA-41BBL resulted in robust Tconv proliferation that was refractory to suppression by Tregs.
Taken together these data demonstrate that costimulation via 4-1BB receptor expressed
on APCs is not involved in SA-4-1BBL-mediated Tconv resistance to suppression by
Treg cells.

TGF- and IFN do not contribute to SA-4-1BBL-mediated evasion from Treg
suppression
TGF-β has been shown to play an important role in the generation of Tregs and
their suppressor function (43-45). We therefore envisioned that SA-4-1BBL stimulation
may overcome the Treg mediated suppression by modulating the function of TGF-β. A
neutralizing Ab against TGF-β at two different doses (8 and 50 µg/ml) did not neutralize
Treg suppression nor did it further improve the observed SA-4-1BBL-mediated evasion
of Treg suppression (Fig. 3).
It has been demonstrated that T cells in response to T-cell receptor signaling
produce an active form of TGF-β, which is adsorbed to the cell surface immediate postsecretion (46). Membrane-bound TGF-β could act as a mediator for Treg suppression
(47). Therefore, to eliminate the possibility that SA-4-1BBL may overcome Treg
suppression by modulating the function of membrane-bound TGF-β, we sorted Tregs and
pre-incubated them with high dose anti-TGF-β Ab (50 µg/ml) for 1 hour prior addition to
coculture suppression assays. These cells were able to suppress Tconvs and costimulation
with SA-4-1BBL was still able to overcome suppression (Fig. 4).
SA-4-1BBL costimulation of Teffs results in their secretion of IFN-γ, which
blocks TGF-β and tumor-mediated conversion of these cells into induced Tregs (35).
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However, opposite findings show that IFN-γ may also contribute to the conversion of
Tconvs into peripheral Tregs and improve their suppressive function by upregulating
Foxp3 gene expression (48). To study the potential role of this cytokine in the observed
SA-4-1BBL-mediated evasion of Treg suppression, we performed suppression assays
with a blocking Ab against IFN-γ (25 µg/ml). The antibody added to the cocultures did
not block the suppression of Tconvs by Tregs, also it provided evidence that IFN-γ is not
responsible for the evasion of suppression in the presence of SA-4-1BBL (Fig. 5). These
observations are consistent with previous findings that IFN-γ has no direct effect on
natural thymic Treg development and function (49).

IL-2 is the major cytokine produced in the supernatant of Tconv:Treg cocultures
costimulated with SA-4-1BBL
In an attempt to identify potential soluble factors that contribute to the Tconv
evasion of Treg suppression, we assessed cytokines generated in coculture supernatants
in response to SA-4-1BBL costimulation using cytokine bead array analysis. As shown in
(Fig. 6), costimulation of Tconvs with SA-4-1BBL resulted in upregulated secretion of all
cytokines tested except IL-17. IL-2 and TNF- production levels were particularly
increased in the 48 hour culture supernatants of Tconvs + SA-4-1BBL. However, the
levels of these two cytokines were similar in supernatants harvested from Tconv:Treg
cocultures with or without SA-4-1BBL costimulation. This cytokine pattern was not time
dependent as 24 hour culture supernatants showed a similar pattern (data not shown).
The presence of APCs and particularly their irradiation may impact overall
cytokine production and secretion into the coculture supernatants. Therefore, these
studies were performed with sorted Tconvs and Tregs in the absence of APCs. IL-2 stood
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out as the highlight cytokine with significant and robust production in supernatants
harvested from Tconvs, as well as Tconv:Treg cocultures costimulated with SA-4-1BBL,
but not in culture supernatants without SA-4-1BBL costimulation (Fig. 7). The lack of
high levels of IL-2 in cultures with irradiated APCs may be due to its non-specific
binding or consumption by such cells, or other unknown mechanisms.
We also noticed a significant drop in the levels of IL-2 in Tconv:Treg cocultures
stimulated with SA-4-1BBL (Fig. 6 and 7) versus Tconvs + SA-4-1BBL cultures. To test
if this is due to IL-2 produced by Tconvs being consumed by Tregs that do not produce
significant levels of this cytokine, we performed quantitative RT-PCR to assess the level
of IL-2 mRNA under various culture conditions. As shown in Figures 8A and 8B, IL-2
transcript levels were comparable between Tconv and Tonv:Treg cocultures stimulated
with SA-41BBL examined at 24 and 48 h time points. Taken together, these data suggest
that the reduced levels of IL-2 protein observed in supernatant of Tconv:Treg coculture
stimulated with SA-4-1BBL is not due to the diminished IL-2 transcript levels, but
possibly because of the consumption of this cytokine by Tregs.

IL-2 is necessary and sufficient for Tconvs to overcome Treg suppression
The high levels of IL-2 production in Tconv:Treg cocultures costimulated with
SA-4-1BBL has captured our interest to test the role of this cytokine in the evasion of
Treg suppression. Culture supernatants from Tconvs + plate-bound anti-CD3 + SA-41BBL for 48 h were harvested and depleted for SA-4-1BBL protein using CuSO4 charged
sepharose beads, taking advantage of the 6xHis Tag engineered into the protein for
purification purposes. The complete removal of SA-4-1BBL was confirmed by Western
blots (Fig. 9). We next subjected this supernatant for removal of IL-2 by first incubating
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with an excessive amount of an anti-IL-2 Ab followed by incubation and removal using
protein G beads. The lack of IL-2 in culture supernatant was confirmed in a CTLL-2
proliferation assay (Fig. 10). Tconv culture supernatants lacking SA-4-1BBL or both SA4-1BBL and IL-2 were tested for their ability to overcome Treg suppression. Addition of
SA-4-1BBL-free culture supernatant resulted in effective evasion of suppression in
Tconv:Treg coculture experiments with (Fig. 11A) or without APCs (Fig. 11B). On the
other hand, culture supernatant lacking both SA-4-1BBL and IL-2 was ineffective in
overcoming Treg suppression. To further confirm that IL-2 is required for overcoming
Treg suppression, Tconv:Treg cocultures were supplemented with recombinant IL-2.
Exogenous IL-2 resulted in robust proliferative responses in both Tconv and Tconv:Treg
cocultures (Fig. 11A, 11B).

IL-2-mediated Tconvs evasion of Tregs suppression is independent of Tregs
proliferative state
In environments where IL-2 is not a limiting factor, both Teffs and Tregs are
known to proliferate upon primary stimulation such as during inflammatory insults (50).
A previous publication by our group also indicates that SA-4-1BBL causes the
proliferation of both Teffs and to a lower extent Tregs (34). Putting one and two together
we have stained either Tconvs sorted from C57BL/6 or Tregs sorted from
C57BL/6.Foxp3hCD2 splenocytes with CFSE prior addition to suppression assays. The
CFSE labeled Tconvs proliferated by 67.5% with SA-4-1BBL and by 64.1% in the
presence of Tregs and SA-4-1BBL. The CFSE labeled Tregs on the other hand
proliferated by 11.1% with SA-4-1BBL and by 27.3% in the presence of Teffs and SA-41BBL (Fig. 12). One might claim here that when Tregs are in an active proliferative state
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they might lose their suppressive capacity and the Tconvs can evade and over-proliferate.
In fact, Tregs at their anergic non-proliferative state are shown to be better suppressors
(51).
To eliminate the contribution of Treg proliferation to the observed evasion of
suppression achieved by SA-4-1BBL, we irradiated sorted-expanded Tregs with 2000
cGy before utilizing them in suppression assays. The irradiated Tregs did not proliferate
upon addition of exogenous IL-2 or SA-4-1BBL and they still maintained their
suppressive function (Fig. 13). More interestingly, when we added SA-4-1BBL to the
cocultures in the presence of irradiated Tregs, Tconvs were still able to proliferate
significantly and escape the suppressive non-proliferative Tregs, which gives us further
confirmation that the mechanism is through IL-2 acting directly on Tconvs in an
autocrine fashion.

Discussion
Our first experiment aimed at reproducing the evasion of suppression data from
previous studies in the lab in the presence and absence of SA-4-1BBL in coculture
suppression assays (36), only this time we have used splenocytes from 41BB-/- mice as
source of irradiated APCs along with soluble anti-CD3. The reason was to eliminate any
interference of 4-1BB receptor on the surface of APCs binding with SA-4-1BBL and
causing the leakage of cytokines such as IL-6, TNF-α, and IL-15, despite irradiation.
Sorted Tconvs cultured with 41BB-/- APCs proliferated successfully in the presence of
SA-4-1BBL and were able to escape suppression when co-cultured with Tregs. The
finding further emphasizes the direct effect of SA-4-1BBL on Tconvs. More Importantly,

24

SA-4-1BBL conferred Tconv resistant to Treg suppression in the complete absence of
APCs.
In an attempt to understand the mechanism of evasion, we initially hypothesized
that if Tregs suppress primarily through TGF-β, SA-4-1BBL might be downregulating
TGF-β receptor II on Tconvs, hence desensitizing them to suppression (52). Adding antiTGF-β neutralizing antibody to the specified cultures (8 µg/ml and 50 µg/ml) did not
block the suppression of Tregs and did not improve the evasion levels noticeably. These
findings are in accordance with published studies demonstrating that thymically derived
(t)Tregs suppress through cell-to-cell contact without a significant contribution by TGF-β
(51, 53). Signaling via 4-1BB receptor on T cells results in IFN-γ production that has the
ability to block TGF-β and tumor-mediated conversion of Tconvs into iTregs (35). On
the other hand, IFN-γ contributes to the conversion of Tconvs into iTregs and enhances
their suppressive function through upregulation of the forkhead box P3 (48). However,
these divergent observations are conducted under different experimental setups as the
first study has used TGF-β and antigen stimulation-dependent conversion, while the
second study has utilized antigen- and a TGF-β-independent conversion setting. In the
present study, a blocking Ab to IFN-γ (25 µg/ml) neither prevented Treg suppression in
the absence of SA-4-1BBL, nor altered SA-4-1BBL-mediated evasion of suppression.
Our data supports previous findings stating that IFN-γ has no direct effect on (t)Tregs
development and function (49).
IL-4 may be another cytokine yet that regulates the balance between Teffs and
Tregs in a twofold fashion: acting on Teffs and activating STAT 6 pathway on one hand
making Teffs resistant to suppression (54, 55), or on the other hand IL-4 may act on
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Tregs and activate GATA 3 that binds in turn to Foxp3 and blocks it (56, 57). The same
studies have reported that the effect of IL-4 is pronounced in iTregs and not nTregs in
general, which dramatically drops the odds of IL-4 involvement in our study since we
have sorted nTregs from naïve mice that are Foxp3+.
IL-2 expressed by Tconvs is required and sufficient for the ability of these cells to
evade Treg suppression under the tested coculture conditions. First, IL-2 was the major
cytokine upregulated in cocultures stimulated with SA-4-BBL in the absence of APCs.
Second, supernatant from SA-4-1BBL-stimulated cultures was effective in overcoming
Treg suppression, and removal of IL-2 nullified this effect. Third, exogenous
recombinant IL-2 alone was effective in overcoming Treg suppression. Competition for
IL-2 has been shown to be an important mechanism that dictates the functional balance
between Tconvs and Tregs. The receptor for IL-2 is a trimeric complex consisting of IL2Rα (CD25), IL-2Rβ (CD122), and IL-2Rγ (CD132). The high affinity receptor CD25 is
constitutively expressed on nTregs while it is upregulated upon induction on Teffs. IL-2
is also known to be a growth factor for Tregs (58), more specifically IL-2 stabilizes the
expression of Foxp3 in iTregs in the presence of TGF-β (59). Our observation is
explained by the fact that in the presence of weak signals such as anti-CD3 and low levels
of IL-2, Tregs that constitutively express CD25 drain all the IL-2 and deprive the Tconvs
from surviving and proliferating (60, 61). On the other hand, a strong costimulatory
molecule such as SA-4-1BBL that provides a potent secondary signal, generates an
abundance of IL-2 and upregulates CD25 on Tconvs allowing them to break from
suppression. Indeed, a recent study using an in vivo imaging approach has demonstrated
that autoantigen-driven Treg clustering with Tconvs on the surface of DCs and
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competition for IL-2 expressed by Tconvs is a major mechanism of autoimmune
suppression (62). A similar IL-2 competition-based suppressive mechanism has recently
been reported for NK cells (63).
The present study demonstrating that SA-4-1BBL targets Tconvs directly for
evasion of Treg suppression is in conflict with another study conducted with agonistic 41BB antibody (64). The authors in the latter state that anti-4-1BB Ab impedes the
suppressive function of Tregs by significantly downregulating the expression of IL-9 in
these cells. They also demonstrate that the combination treatment with CpG-ODN
adjuvant plus anti-IL-9 neutralizing antibody in vivo causes tumor rejection in the
BALBneuT and MUC-1 models (64). However, this study did not provide direct
evidence demonstrating that Tregs are the direct target of agonistic Abs to 4-1BB. The in
vitro evasion of suppression data was obtained using Tconv:Treg cocultures similar to
ours. Also, this study failed to demonstrate the direct role of IL-9 on Treg suppressive
function in vitro. In contrast, our previous study using Tconvs and Tregs from wild type
and 4-1BB KO mice provided direct evidence for Tconvs, but not Tregs, being the target
of SA-4-1BBL for the observed evasion of suppression (36).
In conclusion, our findings that excessive production of IL-2 by Tconvs in
response to SA-4-1BBL costimulation is both necessary and sufficient in overcoming
Treg suppression may have significant implications for treatment of diseases associated
with an imbalance between Tconvs and Tregs, such as cancer. High dose IL-2
immunotherapy against tumors as well as low dose in combination with chemotherapy or
IFN-α treatment has been the subject of several clinical studies since 1980s. The most
pronounced effects were noticed in melanoma and renal cell carcinoma patients (65). The
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toxicity caveat associated with the treatment regimen and administration of exogenous
IL-2 has still yet to be overcome (66). SA-4-1BBL that safely drives the endogenous
production of IL-2 from Teffs could serve as a great alternative without overdosing the
system with excessive amounts of the cytokine.
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CHAPTER 3: SA-4-1BBL AS AN IMMUNE ADJUVANT FOR THE GENERATION
OF PROTECTIVE INNATE AND ADAPTIVE IMMUNE RESPONSES AGAINST
TUMORS
Introduction
Previous studies in our laboratory have demonstrated that SA-4-1BBL as an
adjuvant component of TAA-based subunit vaccine generates robust CD8+ T cell
responses with therapeutic efficacy in various tumor models (27, 36). The SA component
of the molecule is a bacterial antigen extracted from Streptomyces avidinii and has the
potential to generate antibodies following repeated injections. The presence of anti-SA
antibodies (Abs) may play a dual role by enhancing the efficacy of the vaccine through
crosslinking the SA-4-1BBL molecules, hence leading to better receptor clustering and
signaling. On the other hand, anti-SA Abs may bind and neutralize the effect of the SA-41BBL molecule by blocking its interaction with 4-1BB or accelerating its in vivo
clearance.
In order to understand the positive or negative side effects of antibodies produced
against vaccine immunogens, it is best to refer to studies concerning anti-drug antibodies
(ADAs) against persistent biologics and protein treatments. For example, patients on
adalimumab treatment for rheumatoid arthritis showed lower response rates in the
presence of anti-adalimumab Abs, which directly correlated to lower levels of the
adalimumab drug in their sera (67). Yet another study explored the effect of ADAs
against infliximab, etanercept, adalimumab and ustekinumab in treated patients with
psoriasis (68). The presence of anti-infliximab and anti- adalimumab Abs was associated
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with lower serum drug concentrations, while anti-etanercept Abs had no apparent effect.
Anti-ustekinumab antibodies played both positive and negative roles against psoriasis in
separate studies. Therefore, a review of data shows that not all cases positive for ADAs
have a loss of drug efficacy or cause hypersensitivity reactions.
In this particular chapter, we explore the solo role of SA-4-1BBL costimulatory
molecule and its impact on the immune system. The SA portion is a biological agent that
carries several epitopes that can be recognized by T and B cells. In some studies it is
suggested to reduce the immunogenicity of SA through the concomitant administration of
methotrexate, or the use of mutated forms of the de-immunized protein with less
antigenic epitopes, while maintaining tetramer forming and biotin binding capacities of
the molecule (69, 70). Other studies exploit the use of immunogenic SA to the advantage
of vaccine development and treatment. For example, vaccination with soluble tumor
proteins conjugated to SA has been shown to be effective in the 9L rat glioma model
(71). In that study, antibodies against SA were detected in the immunized rats. However,
Ab levels did not correlate with the anti-tumor response. Similarly, we show below that
pre-treating mice with SA-4-1BBL protects against subsequent tumor challenges without
interfering in post-tumor vaccine outcomes and without contribution from anti-SA
antibodies. An insight into the mechanism of action of SA-4-1BBL and its role in antitumor immunity is further demonstrated and discussed in this chapter.
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Materials and Methods
Mice
C57BL/6 mice were purchased from The Jackson Laboratory. C57BL/6.4-1BB knockout
mice (40) and 4C mice (72) were bred and cared for in a University of Louisville specific
pathogen-free animal facility in accordance with NIH guidelines. All animal procedures
were approved by the University of Louisville’s IACUC.

Antibodies and Reagents
Antibodies used include anti-CD3 agonistic Ab (clone 145-2C11, BD Pharmingen, Cat#
553058). Fluorescent-conjugated Abs to various cell surface markers were obtained
commercially: anti-CD3-V500 (BD Horizon 560771); anti-CD4-Alexa700 (BD
Pharmingen 557956); anti-CD8-APC-Cy7 (BD Pharmingen 557654); anti-NK1.1-PE
(BD Pharmingen 553165); anti-CD19-APC (BD Pharmingen 550992); anti-CD44-APC
(eBioscience 17-0441-83); anti-CD62L-PerCp-Cy5.5 (eBioscience 45-0621-82). Anti-41BB agonistic Ab (clone 3H3) was produced and purified in our Lab. 500 µg/mouse of
depletion antibodies were injected i.p. in specified experiments including anti-CD4 Ab
(clone GK1.5); anti-NK1.1 Ab (clone PK 136); anti-CD8 Ab (clone 53.6.72); and antiCD20 Ab 200 µg/mouse (clone 5D2).
SA-4-1BBL and SA proteins were produced in our lab according to standard protocols as
previously reported (34, 41, 42). TC-1 tumor cell line was obtained from American Type
Culture Collection (ATCC).
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Immunization strategy and tumor challenge
Several groups of mice were challenged subcutaneously (s.c.) with 2 shots of SA-4-1BBL
(25 µg) on days 0 and 14. Unless specified, mice were injected two weeks later s.c. with
1 x 105 cells of TC-1 tumor cell line. TC-1 is originally derived from lung epithelial cells
of C57BL/6 mice and transfected to express the human papillomavirus HPV-E6 and E7
proteins. In certain groups, mice also received post tumor challenge vaccination with 50
µg E7-P1 peptide (RAHYNIVTF) + 25 µg SA-4-1BBL (Fig. 14). Tumors were
monitored and measured twice a week using calipers over a period of 60 days or until
tumor average diameter reaches its endpoint (12 mm). In select experiments, Lewis Lung
Carcinoma (LLC) cell line was used instead of TC-1. For long term memory studies,
tumor free mice at the experimental endpoint were re-challenged with 1 x 105 cells of TC1 and monitored for at least additional 60 days.

Enzyme-linked immunosorbent assay (ELISA) for serum antibodies and subtyping
Blood was collected and serum isolated from different groups of mice 1 week after the
2nd immunization with SA-4-1BBL and at experimental end points. ELISA plates were
coated overnight with 50 ng of either SA-4-1BBL or SA proteins. Next day plates were
washed, blocked with milk, and incubated with serial dilutions of specified sera for 1.5
hours at room temperature. After that, secondary antibodies conjugated to horseradish
peroxidase enzyme (HRP) were added for 1 hour to measure for total IgG titers as well as
several isotypes including IgG1, IgG2b, IgG2c, IgG3, IgM, and IgA. Plates were
incubated for 30 min with TMB substrate (BD Biosciences, Cat#555214), reaction was
stopped with 2N H2SO4 and plates were read for colorimetric reaction at 450 nm.
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Adoptive serum transfer
Sera collected on Day 27 from SA-4-1BBL-immunized mice (25 µg on days 0 and 14
s.c.) were adoptively transferred to naïve C57BL/6 mice (200 µl i.v.) 24 hours prior to
TC-1 tumor challenge (1 x 105 cells s.c.). Sera antibody titers were tested by ELISA
against SA prior to transfer. Tumor diameters were measured twice a week using calipers
over a period of 60 days or until tumor average diameter reaches its endpoint (12 mm).

Anti-CD3 proliferation assay
C57BL/6 splenocytes (2 x 105 cells/well) were cultured in 96-well U-bottom plates and
stimulated with anti-CD3 agonistic antibody (0.025 µg/ml) and serially diluted doses of
SA-4-1BBL in the presence or absence of mice serum pre-immunized twice with 25 µg
of SA-4-1BBL. Cultures were incubated for 48 h and pulsed with [3H]-thymidine for an
additional 16 h. Plates were harvested with Tomtec Cell Harvester and proliferative
counts were measured with a Beta plate counter and reported as CPM.

Flow cytometry and phenotyping
Spleens and draining lymph nodes from naïve, 12.5 µg SA + 100 µg 3H3 immunized, or
25 µg SA-4-1BBL immunized C57BL/6 mice were harvested at different time points and
processed into single cell suspensions. One million cells of each sample were stained
with fluorescent-conjugated antibodies with corresponding compensation and isotype
controls for flow cytometry. CD4+ T cells and CD8+ T cells were gated on CD3+
population. B cells were gated on CD19+, NK cells were gated on CD3- and NK1.1+.
NKT cells were gated on CD3+ and NK1.1+. Cell percentages as well as absolute cell
numbers were calculated and reported. For memory phenotyping, CD3+ CD62Llo CD44hi
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T cells were characterized as T-effector memory, while CD3+ CD62Lhi CD44hi were
characterized as T-central memory.

Statistics
At experimental end points, Kaplan-Meier survival curves were graphed and log-rank
statistical method was applied between groups using GraphPad software, with p ≤ 0.05
considered significant.

Results
Streptavidin portion of SA-4-1BBL is immunogenic
To assess the immunogenicity of SA-4-1BBL, a group of C57BL/6 mice (Group
1) was immunized twice with 25 µg of SA-4-1BBL via s.c. injection on days 0 and 14.
Blood was withdrawn and isolated serum was tested by ELISA for humoral responses
one week before TC-1 tumor challenge, one week after tumor challenge, and at
experimental endpoint (Fig. 14). ELISA plates pre-coated with SA-4-1BBL (Fig. 15) or
SA (data not shown) had comparable total IgG titers. Serum antibody titers were positive
on day 21 (4 out of 5 animals), slightly elevated on day 34 (5 out of 5), then slightly
reduced on day 90 (Fig. 15). A second group of mice (Group 2) was treated with the
same regimen, except that this group also received a subunit vaccine consisting of a
peptide (P1) representing the dominant CD8+ T cell epitope for HPV E7 antigen and SA4-1BBL on day 36. Antibody titers were tested positive on day 21 (2 out of 5 animals),
elevated on day 34 (5 out of 5), then slightly reduced on day 90 (Fig. 15).
We next subtyped the Abs to assess the nature of immune responses generated.
IgG1 isotype is usually indicative of Th2 responses while IgG2a is associated with Th1
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responses (73). IgM is mainly upregulated during primary immune responses and
undergoes class switching during secondary responses. T-helper independent antibody
production on the other hand favors the IgG3 subtype. Subtyping ELISA for group 1 on
days 21 and 90 (Fig. 16) revealed IgG1 and IgM to be the major isotypes upregulated
upon SA-4-1BBL immunization.
The positive humoral immune response led us to test if SA also generates CD4+ T
cell responses. Mice were immunized once with SA-4-1BBL. Seven days later spleens
from naïve as well as immunized mice were harvested, processed, and cultured in vitro
for 48 hours in the presence or absence of SA stimulation. Cultures were pulsed with
3

[H]-thymidine for additional 16 hours and CPMs were recorded. SA was capable of

generating more than 3 fold T cell proliferative responses in SA-4-1BBL immunized
cultures as compared to naïve background (Fig. 17).

Anti-SA Abs do not negatively impact the costimulatory function of SA-4-1BBL in
vitro and in vivo
To test if anti-SA antibodies hinder or augment the costimulatory function of the
SA-4-1BBL molecule, we conducted an in vitro proliferation assay with SA-4-1BBL
costimulation-driven expansion of T cells as a read out. In brief, naïve C57BL/6
splenocytes were stimulated with the agonistic anti-CD3 Ab in the presence of SA-41BBL incubated with naïve (set 1) or pre-immunized (set 2) serum (Fig. 18). The preimmunized serum containing anti-SA antibodies did not alter the ability of SA-4-1BBL to
deliver its costimulatory signal, as set 2 splenocytes proliferated as efficiently as set 1 in
vitro.
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Following the experimental design demonstrated in Figure 14, we assessed if the
in vivo-generated anti-SA antibodies, produced by repeated injections with SA-4-1BBL,
might modify the post-tumor vaccination outcome with the E7 peptide-based vaccine in
the transplantable TC-1 tumor model. As depicted in the survival curve in Figure 19,
administering SA-4-1BBL twice not only left the post-tumor vaccine efficacy intact, but
also induced 100% tumor protection by itself up to 70 days after tumor challenge.

Pretreatment with SA-4-1BBL generates a prolonged window of immune responses
against TC-1 tumor
In order to understand the dynamics of the SA-4-1BBL anti-tumor immune
response observed in Figure 19, we next performed extensive time-course preimmunization studies in C57BL/6 mice receiving TC-1 tumors at different time points
after prime or prime/boost immunizations with SA-4-1BBL. As shown in Fig. 20A and
20B, 1 shot of SA-4-1BBL, 1 day later or 1 week later TC-1 challenge protocols did not
confer any tumor protectivity, suggesting that immediate innate immune response alone
is not sufficient. On the other hand, administering TC-1 two weeks after SA-4-1BBL
immunization, showed around 40% survival (Fig. 20C), which provides enough time for
adaptive immunity to kick in.
In a second set of studies, we observed 40% survival with 2 shots of SA-4-1BBL,
1 day later TC-1 challenge (Fig. 21A); 100% survival with 2 shots of SA-4-1BBL, 1
week later TC-1 (Fig. 21B); 100% survival and 80% survival were recorded with 2 shots
of SA-4-1BBL, 4 weeks and 8 weeks later TC-1 injection respectively (Fig. 22A); but we
noticed a significant drop in survival for the 2 shots SA-4-1BBL, 12 weeks later TC-1
challenged group (Fig. 22B).
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SA-4-1BBL generates long-term immune memory against TC-1
Our study design to test for protection against TC-1 recurrences was as follows:
naïve C57BL/6 mice were immunized twice with SA-4-1BBL (2 weeks apart), followed
by 1st TC-1 tumor cells challenge 2 weeks after the second immunization. Mice were
monitored for a period of 60 days after 1st tumor injection. At the end of the 60 days,
tumor free mice were rechallenged with a 2nd shot of TC-1 tumor cells and monitored for
another 80 days (Fig. 23). As shown, pre-immunization with SA-4-1BBL alone
significantly delayed the onset and growth rate of tumors after 2nd TC-1 challenge, hence
establishing a long term memory effect. Pre-immunization + post-tumor vaccination
group establishes a different type of memory that is specifically directed towards E7-P1
tumor antigen and is mediated through IFN-γ and CD8 cells (27) where we clearly obtain
60% survival even after 80 days from 2nd tumor challenge (Fig. 23).
Phenotyping of spleens (spls) and draining lymph nodes (dLNs) for the SA-41BBL pre-immunized group 60 days post-tumor injection revealed a significant increase
in the CD4+ T effector memory compartment both in spls and dLNs. In addition, the
CD4+ T central memory compartment was elevated in the draining lymph nodes of these
mice (Fig. 24).
The protective effect of pretreatment with SA-4-1BBL is tumor-type independent
We hypothesized that since the SA-4-1BBL-generated immune response was
independent from tumor specific antigens, then the type of the transplantable tumor used
would not affect the outcome. To test this, C57BL/6 mice were immunized twice with 25
µg SA-4-1BBL (2 weeks apart), followed by Lewis Lung Carcinoma (LLC) or TC-1
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tumor challenge 2 weeks after the 2nd immunization. Indeed, pre-immunization with SA4-1BBL alone showed significant protection against LLC relative to TC-1 (Fig. 25).

Anti-SA Abs do not play a role in the protective effect of pretreatment with SA-41BBL against TC-1 tumor
Humoral immunity has been shown to play a role in the efficacy of various cancer
immunotherapies. Antibodies can have a direct effect on the tumor by recognizing and
binding to surface antigens, or by helping antigen-presentation and processing by APCs
through opsonization, thereby augmenting downstream adaptive immune responses.
Given the positive titers of SA-Abs in the pretreatment setting, we asked if such Abs can
contribute to the protective effect we observe against TC-1 tumors. Towards this goal,
sera were collected on day 27 from SA-4-1BBL immunized mice (25µg on days 0 and
14) and adoptively transferred into naïve C57BL/6 mice (200 µl/mouse) 24 hours prior to
TC-1 tumor challenge. Anti-SA Abs in adoptively transferred sera did not show any
significant protection and all the recipient mice expired similar to TC-1 control (Fig. 26).

Protective effect of SA-4-1BBL against tumor involves a cross-talk between NK and
CD4+ T cells
The lack of a positive effect of anti-SA Abs on tumor protection led us to
hypothesize that protection involves cellular immunity. In search for target effector cells,
and in the light of our previous findings about the role of NK cells in tumor protection
(27), we conducted 2 sets of NK depletion studies with reference to Figure 14 design. In
the first set, NK cells were depleted with anti-mouse NK1.1 Ab 1 day prior to each
immunization with SA-4-1BBL (days -1 and 13). In the second set, NK cells were
depleted once 1 day before TC-1 tumor challenge (day 27). Mice were monitored for
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additional 60 days after tumor injection and survival assessed at the experimental
endpoints (Fig. 27). In both sets of experiments, depletion of NK cells significantly
compromised SA-4-1BBL efficacy against TC-1 tumors.
In the same fashion, CD4 cells were depleted using anti-CD4 Ab during 2 distinct
phases. The initiation phase covers the first 27 days before TC-1 challenge where CD4
cells were depleted 1 day prior to immunizations with SA-4-1BBL (Fig. 28), and the
effector phase covers the 60 day period after TC-1 challenge where CD4 cells were
depleted 1 day before TC-1 injection (Fig. 29). In both phases, the presence of CD4 cells
was critical in driving and maintaining the SA-4-1BBL-mediated anti-tumor effect.
Surprisingly, depletion of CD8 cells 1 day prior to SA-4-1BBL immunizations did not
abrogate the anti-tumor effect (Fig. 28).
In order to discount any role of B cells or contribution from antibodies in the
observed SA-4-1BBL-mediated anti-tumor immunity, we depleted B cells with an antiCD20 antibody during the initiation phase (1 day before SA-4-1BBL immunizations). In
the absence of B cells, SA-4-1BBL still induced 100% survival against TC-1 (Fig. 30),
showing the lack of dependence on B cells and anti-SA antibodies.

CD4 cells should recognize SA for optimal anti-tumor protectivity
To further confirm the importance of the CD4+ T cell responses to the observed
protective effect of SA-4-1BBL pretreatment, we used the 4C T-cell receptor transgenic
mice where 99% of the CD4 T cells express the vβ13 chain and exclusively recognize
allogeneic Balb/c MHC class II antigen. Due to this specificity, these mice should not
recognize SA upon SA-4-1BBL immunization. Indeed, pre-immunization with SA-41BBL was futile in these mice and tumor protectivity against TC-1 was lost (Fig. 31),
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although we noticed a non-significant delay in tumors expiration as compared to 4C
controls injected with TC-1 alone. We also noticed attenuated T cell proliferation in 4C
mice first immunized with SA-4-1BBL for 7 days, followed by stimulation in vitro with
SA antigen, as compared to wild type C57BL/6 mice (Fig. 32). On the other hand, this
minimal recognition of SA in 4C mice was sufficient to generate anti-SA antibodies (Fig.
33), which further confirmed our previous observation that antibodies themselves are not
protective, as all mice expired from tumor burden. Sera collected from SA-4-1BBLimmunized 4C mice was subjected to subtyping ELISA resulting in detection of high
levels of IgM and IgG1 isotypes and low levels of IgG2b and IgG2c as compared to
immunized B6 control (Fig. 34).

The anti-tumor effect of SA-4-1BBL is a unique property of this molecule and is not
achieved using agonistic Ab to the receptor
We have previously shown qualitative and quantitative difference between SA41BBL and agonistic Ab to 4-1BB (23). We therefore tested if the anti-tumor protection
of SA-4-1BBL is a unique property of this molecule or it can be extended to any agonist
of 4-1BB receptor. Different groups of C57BL/6 mice were immunized twice with either
SA alone (12.5 µg), 3H3 alone (100 µg), SA + 3H3, or SA-4-1BBL (25 µg), followed by
TC-1 challenge 2 weeks after the 2nd immunization. Pre-immunization with 3H3 alone,
SA alone, or with SA + 3H3 did not result in any tumor protection compared to the TC-1
control group (Fig. 35). On the other hand, pre-immunization with SA-4-1BBL has
demonstrated a unique attribute in rejecting subsequently challenged tumors by reaching
80 to 100% survival.
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Lymphocyte percentages and absolute cell number analysis in spleens of mice
immunized twice with SA + 3H3 vs. SA-4-1BBL showed a significant reduction in NK
cells in the SA + 3H3 group (Figs. 36, 37). This could be a direct effect of 3H3 on NK
cells since they express the 4-1BB receptor, or it could be the result of 3H3 blocking the
function of a helper cell population providing assistance to NK cells such as CD4+ T
cells. On the other hand, analysis of draining lymph nodes of the immunized mice
showed reduced percentages of NK cells but not absolute cell numbers in the SA + 3H3
treated group (Figs. 38, 39). This observation could be attributed to the toxicity and
lymphadenopathy associated with 3H3 treatment, since the lymph nodes harvested were
significantly larger in size and had greater total cell counts as compared to the SA-41BBL treated group (data not shown).
Moreover, we noticed a shutdown in anti-SA antibody production in the group
immunized with SA + 3H3 twice (Fig. 40). Sera was collected on day 21 (1 week after
2nd immunization) and at tumor endpoints, and was subjected to ELISA. We have
previously demonstrated in this chapter that the lack of anti-SA antibodies has no effect
on tumor rejection, which suggests a direct negative role of 3H3 on CD4+ T cells in this
case.
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Discussion
Our hypothesis was that, since SA portion of SA-4-1BBL is a foreign bacterial
antigen, repeated immunizations with SA-4-1BBL might generate desirable or nondesirable immune responses affecting the overall efficacy of the therapeutic anti-tumor
vaccine. Indeed, immunizations with SA-4-1BBL generated anti-SA antibodies detected
in mice sera over a period of 90 days. We initially thought that these antibodies might be
able to activate NK cells through antibody-mediated cell cytotoxicity (ADCC) leading to
tumor eradication. Ideally, for that to take place the tumors should express SA antigen.
Upon testing TC-1 tumor lysates by Western blotting, SA protein was not detected (data
not shown), although we cannot exclude the possibility of cross-reactivity occurring with
another tumor-associated protein that resembles SA. Antibodies on the other hand may
also play a negative role, since they may be recruited by the tumor to mask itself and
evade immunity. Anti-SA antibodies may also potentially bind to the SA-4-1BBL
molecule hindering its efficacy or neutralizing its effect. Our data here show that anti-SA
Abs do not have an effect on the costimulatory function of the SA-4-1BBL molecule
either in vitro or in vivo.
Based on our previous work, vaccination with E7 + SA-4-1BBL had ~70%
therapeutic efficacy in the TC-1 model (27). Therefore, the observed 100% therapeutic
efficacy against TC-1 tumor with the subunit vaccine in the SA-4-1BBL pretreatment
setting was surprising (Fig. 19), and led us to further test the immune responses generated
with SA-4-1BBL treatment alone. One shot of SA-4-1BBL, one day or one week later
TC-1 challenge, did not show any anti-tumor effect suggesting that initial innate immune
responses alone are not sufficient. Two shots of SA-4-1BBL treatment regimen, followed
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by TC-1 challenge one, two, four, or eight weeks afterwards showed full anti-tumor
protection. This prolonged SA-4-1BBL effect suggests the involvement of adaptive
immunity which can further sustain innate immune activity.
Mechanistic studies aiming at identifying effector immune cells involved in the
observed SA-4-1BBL protection were conducted. Inasmuch as our previous studies have
demonstrated the critical role of CD8+ T cells in vaccine efficacy (26), we depleted these
cells one day before pretreatments with SA-4-1BBL followed by TC-1 tumor challenge
after two weeks. Immunized mice suppressed tumor growth, discounting the potential
involvement of CD8 cells. The interplay between NK cells and CD4 cells was proven
critical for maintaining a prolonged effect against tumors as shown by the depletion
studies. During the initiation phase, SA-4-1BBL may be acting on NK cells that express
4-1BB receptor on their cell surface (28), CD4+ T conventional cells, or on both cell
types simultaneously. After tumor challenge and during effector phase, the presence of
CD4 cells proved essential for maintaining the anti-tumor effect observed. In addition to
that, SA-4-1BBL’s effect was not directed towards B cells, as depletion of such cells
before immunizations did not interfere in protection from tumor. The later observation
further confirmed that anti-SA antibodies generated by plasma cells do not play a role.
Adoptive serum transfer of SA-4-1BBL-immunized sera to naïve mice prior to tumor
challenge strongly suggests a lack of antibody protectivity.
Our data indicate that pretreatment of mice with SA-4-1BBL chimeric protein
establishes a communication bridge between NK and CD4+ T cells. To further test the
hypothesis, we used 4C TCR transgenic mice pre-immunized twice with SA-4-1BBL
prior to TC-1 tumor challenge. CD4+ T cells in these mice did not recognize, or at least
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did not optimally recognize SA as antigen; hence all mice expired due to tumor burden
despite the presence of NK cells and treatment with SA-4-1BBL. It is important here to
recall that 4-1BB expression on CD4+ T cells is inducible and requires an initial signal,
apparently provided by SA in this case, to be upregulated and to deliver effective
costimulatory signals. The importance of CD4+ T cells shown here is in agreement with
our therapeutic vaccine data published earlier emphasizing the effect of SA-4-1BBL on
CD4+ T cells (25). Depletion of CD4 cells one day before tumor challenge resulted in
compromised vaccine efficacy delivered after six days, and depletion of CD4 cells one
day before vaccine led to loss of long-term immunological memory against Lewis lung
carcinoma (25).
Several studies in the literature suggest IL-2 cytokine to be fundamental for CD4NK communication in overcoming tumors and fighting infectious microbes. HIV-1 viral
infection provides a good example, where CD4+ T cell numbers are compromised along
with their IL-2 production, leading to NK cells anergy and irresponsiveness to infection
(74). In the same study, subjects immunized with HIV-1 subunit vaccine showed
increased IL-2 production by Gp120-specific CD4+ T cells associated with higher IFN-γ
levels produced by NK cells (74). In another study conducted in CD8 α-chain KO mice,
collaboration between CD4+ T cells and NK cells was critical in fighting B16 melanoma
tumors upon delivery of non-antigen-loaded immature dendritic cell vaccine (75).
Another clinically relevant report demonstrated that CD56bright NK cells isolated from
human subjects constitutively express the high-affinity IL-2 receptor. These NK cells
produced higher levels of IFN-γ when cocultured with CD4+ T cells producing IL-2
cytokine upon activation with tetanus toxoid (76). Moreover, human NK cells activated
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by IL-2 and NKG2D receptor or CD16 were shown to upregulate OX40L expression on
their surface, costimulating CD4+ T cells expressing OX40 to produce IFN-γ (77). In the
dLNs of mice newly infected with Leishmania major parasite, CD4+ T cells were shown
to directly activate NK cells through the production of IL-2 or indirectly through the
regulation of IL-12 secretion by dendritic cells (78). The cross-talk between innate and
adaptive immunity through IL-2 was also emphasized in a malaria infection setting with
special focus on NK and CD4+ T cells interacting together in an MHC class II-dependent
manner (79).
Killer Eomes+ KLRG1+ CD4+ T cells (17), capable of producing granzymes and
fighting melanoma cells, don’t seem to be involved in SA-4-1BBL’s anti-tumor effect.
While conducting our pre-immunization mechanistic studies, we depleted NK cells 1 day
before TC-1 while leaving CD4 cells intact and subject to activation by SA-4-1BBL.
Regardless of the presence of any killer CD4+ T cells during priming and effector phases,
the lack of NK cells voided SA-4-1BBL’s effect and all mice expired.
In this study we recognized and established the unique anti-tumor property of the
SA-4-1BBL molecule, not achieved otherwise using agonistic Ab to the receptor. In our
hands, anti-tumor protection was lost when mice were immunized with SA + 3H3. We
also observed the shutdown of antibody production against SA in the presence of 3H3.
Our observation is in accordance with published literature suggesting that monoclonal
agonistic antibodies against 4-1BB can block antibody production by B cells, a method
used in the treatment of autoimmune diseases such as Systemic Lupus Erythematosus
(SLE) and Graft-versus-host disease (GVHD) (80, 81). The mechanism seems to be
mediated by inducing anergy of helper T cells, which in turn cease to provide help to B

45

cells, halting their antibody production (82). Moreover, we have also noticed a reduction
in the percentages and absolute cell numbers of NK cells in mice pretreated with SA +
3H3, but not SA-4-1BBL. This may be due to the indirect deleterious effect of 3H3 on
CD4+ T helper functions, or it may be due to direct engagement of 3H3 with its receptor
on NK cells. The effect of agonistic antibodies to 4-1BB on NK cells is controversial in
the literature. Some of the studies reporting positive aspects include human NK cells
activated by trastuzumab in breast cancer treatment which upregulated 4-1BB, and
further stimulation with anti-4-1BB Ab killed breast cancer cells (83). Similarly, the antilymphoma activity of rituximab was improved by stimulation of NK cells with anti-41BB monoclonal antibody (84). Others also reported regulatory aspects of NK cells in
anti-tumor settings without having cytolytic activity (85). In that study, CD137stimulated helper NK cells successfully proliferated and produced IFN-γ to augment
CD8+ cytotoxic T lymphocytes, but did not directly kill p815 mastocytoma tumor cells.
On the other hand, several studies report the negative role of anti-4-1BB stimulation on
NK cells including toxicity and excessive systemic inflammation in mice and humans
(15, 23). Overproduction of IFN-gamma by CD8+ T cells and NK cells upon stimulation
with anti-4-1BB Ab was shown to downregulate the frequency and number of NK cells in
the spleens and bone marrows of tumor-bearing mice. NK numbers were otherwise
restored in 4-1BB knockout mice (86).
In conclusion, our data collectively confirm SA-4-1BBL to be a bona fide
immune modulator possessing anti-tumor properties, successfully bridging innate and
adaptive immunities with vast clinical applications. SA-4-1BBL immunotherapy provides
a better and safer alternative for clinically applied agonistic TNFR antibodies, and/or
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standard treatment regimens such as chemotherapy or radiotherapy that bear several side
effects. Deciphering the detailed mechanism(s) of communication between CD4+ T cells,
NK cells, and other accessory immune cells in pre-clinical settings, will definitely help in
future development of preventative as well as therapeutic anti-tumor vaccines. Towards
that end, our future experiments will aim at monitoring and studying the nature and levels
of cytokines produced upon SA-4-1BBL versus 3H3 and SA + 3H3 pre-immunizations as
well as the cellular phenotypes associated (successfully activated and functional versus
anergic and irresponsive). We will also explore the possibility of combining innate
immune adjuvants such as monophosphoryl lipid A (MPL) and/or other TNF
costimulatory molecules such as OX40L with SA-4-1BBL in pre-immunization settings
in order to reach ultimate preventative anti-tumor protection with prolongation in
immune responses against metastatic tumor recurrences.
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Figure 1. Costimulation by SA-4-1BBL overcomes suppression of Tconvs by Tregs
independent of APCs. Flow-sorted Tconvs were cocultured with freshly sorted or
expanded Tregs at 1:1 ratio in the presence of irradiated splenocytes from wild type or 41BB-/- mice as APCs and anti-CD3 Ab (0.5 µg/ml). SA-4-1BBL (1 µg/ml) was added to
cultures where indicated. Cultures were incubated for 48 h, pulsed with [3H]-thymidine
for an additional 16 h, and proliferation was measured and graphed as cpm. Each data
point is indicative of mean ± SEM of triplicate wells and representative of 2 separate
experiments. Student’s t-test (two-tailed) was performed for statistical analysis with *p ≤
0.05 being significant.

48

*

(cpm x 103)

40
30

*

20

10
0

Figure 2. Costimulation by SA-4-1BBL overcomes suppression of Tregs to Tconvs in
absence of APCs. Suppression assay was conducted with sorted Tconvs and Tregs
without APCs using plate bound anti-CD3 Ab (5 µg/ml) and soluble SA-4-1BBL (1
µg/ml) where indicated. Each data point is indicative of mean ± SEM of triplicate wells
and representative of 2 separate experiments. Student’s t-test (two-tailed) was performed
for statistical analysis with *p ≤ 0.05 being significant.
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Figure 3. TGF-β cytokine is not involved in Tconv evasion of Treg suppression. Sorted
Tconvs and Tregs were cocultured at 1:1 ratio in the presence of irradiated APCs and
anti-CD3 Ab (0.5 µg/ml). Cultures were also supplied with SA-4-1BBL (1 µg/ml) and
blocking Ab to TGF- (either 8 or 50 µg/ml) at the time of incubation. Each data point is
indicative of mean ± SEM of triplicate wells and representative of 2 independent
experiments. Student’s t-test (two-tailed) was performed for statistical analysis with *p ≤
0.05 being significant.
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Figure 4. Cell surface-bound TGF-β is not involved in Tconv evasion of Treg
suppression. Sorted Tconvs and Tregs were cocultured at 1:1 ratio in the presence of
irradiated APCs and anti-CD3 Ab (0.5 µg/ml). Cultures were supplemented with Tregs
pre-incubated with anti-TGF-β Ab (50 µg/ml), then stimulated with SA-4-1BBL (1
µg/ml) wherever indicated. Each data point is indicative of mean ± SEM of triplicate
wells and representative of 2 independent experiments. Student’s t-test (two-tailed) was
performed for statistical analysis with *p ≤ 0.05 being significant.
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Figure 5. IFN-γ cytokine is not involved in Tconv evasion of Treg suppression. Sorted
Tconvs and Tregs were cocultured at 1:1 ratio in the presence of irradiated APCs and
anti-CD3 Ab (0.5 µg/ml). Cultures were also supplied with SA-4-1BBL (1 µg/ml) and
anti-IFN- blocking antibody (25 µg/ml). Each data point is indicative of mean ± SEM of
triplicate wells and representative of 2 independent experiments. Student’s t-test (twotailed) was performed for statistical analysis with *p ≤ 0.05 being significant.
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Figure 6. IL-2 is a predominant cytokine upregulated in Tconv and Tregs cocultures
costimulated with SA-4-1BBL. Sorted Tconvs and Tregs were cocultured at 1:1 ratio and
48 h later supernatants were collected and subjected to cytometric bead array analysis.
Cultures contain irradiated APCs, SA-4-1BBL (1 µg/ml) as shown, and soluble anti-CD3
Ab (0.5 µg/ml). Data shown is combination of two independent experiments with mean ±
SEM reported.
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Figure 7. IL-2 is the predominant cytokine upregulated in Tconv and Tregs cocultures
costimulated with SA-4-1BBL without APCs. Sorted Tconvs and Tregs were cocultured
at 1:1 ratio and 48 h later supernatants were collected and subjected to cytometric bead
array analysis. Cultures were stimulated with plate bound anti-CD3 Ab (5 µg/ml) and
SA-4-1BBL (1 µg/ml) as indicated. Data shown is combination of two independent
experiments with mean ± SEM reported.
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Figure 8. RT-PCR ∆∆CT values for relative IL-2 mRNA expression with respect to
GAPDH gene in indicated cultures stimulated with SA-4-1BBL (1 µg/ml) and platebound anti-CD3 Ab (5 µg/ml). IL-2 expression was assessed at 24 (A) and 48 (B) hours
post-stimulation. Each data point represents the mean of triplicate wells ± SD, with *p ≤
0.05 being significant.
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Figure 9. Removal of SA-4-1BBL from Tconv culture supernatants. Supernatant (sup) of
Tconvs stimulated with an agonistic anti-CD3 Ab (5 µg/ml) and SA-4-1BBL (1 µg/ml)
were incubated with CuSO4-charged sepharose beads to remove SA-4-1BBL carrying a
6xHis tag. Regular sup (batch 1) and SA-4-1BBL-depleted sup (batch 2) were analyzed
using anti-SA antibodies for detection in Western blots. The indicated amounts of SA-41BBL protein were used as detection controls.
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Figure 10. Removal of IL-2 from Tconv culture supernatants. Batch 2 supernatant,
cleaned from SA-4-1BBL as described in Figure 9, was incubated with an anti-IL-2 Ab
(20 µg/ml) followed by the removal of Ab/IL-2 complexes using immobilized protein G
beads to generate batch 3. Batch 2 as well as batch 3 supernatants (50 µl/each) were
tested on the IL-2-dependent CTTL-2 cell line with the indicated commercial
recombinant IL-2 doses (IU/ml) as positive and PBS as negative controls. Cultures were
incubated for 28 h with [3H]-thymidine added for the last 8 h. Proliferation was measured
and graphed as cpm. Each data point is indicative of mean ± SEM of triplicate wells.
Student’s t-test (two-tailed) was performed for statistical analysis with *p ≤ 0.05 being
significant. The data is representative for two independent experiments.
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Figure 11. SA-4-1BBL costimulation-mediated IL-2 production by Tconvs is both
necessary and sufficient in overcoming Treg suppression. Sorted Tconvs and Tregs were
cocultured at 1:1 ratio in the presence (A) or absence (B) of irradiated APCs and antiCD3 Ab. Cultures were also supplemented with SA-4-1BBL (1 µg/ml), IL-2 (3 IU/ml),
SA-4-1BBL-depleted supernatants (100 µl/well), or SA-4-1BBL- and IL-2-depleted
supernatants (100 µl/well) where indicated. Each data point is indicative of mean ± SEM
of triplicate wells. Student’s t-test (two-tailed) was performed for statistical analysis with
*p ≤ 0.05 being significant.
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Figure 12. Tconvs proliferate to a higher extent upon SA-4-1BBL stimulation as
compared to Tregs. Tconvs sorted from WT C57BL/6 or Tregs sorted from
C57BL/6.Foxp3hCD2 mice were labeled with 2.5µM CFSE and used in coculture
suppression assays with irradiated APCs. Cultures were incubated for 64 h and cells were
analyzed for proliferation using LSRII flow cytometer.
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Figure 13. IL-2-mediated Tconvs evasion of Tregs suppression is independent of Tregs
proliferative state. Sorted Tconvs and Tregs were cocultured at 1:1 ratio in the presence
of APCs and anti-CD3 Ab (0.5 µg/ml). Cultures were also supplemented with SA-41BBL (1 µg/ml) or IL-2 (3 IU/ml) wherever indicated. In select cultures, Tregs were
irradiated at 2000 cGy (Tregs*) prior use. Each data point is indicative of mean ± SEM of
triplicate wells. Student’s t-test (two-tailed) was performed for statistical analysis with *p
≤ 0.05 being significant. Experiment repeated twice with similar pattern detected.
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Figure 14. Schematic time line to study SA-4-1BBL’s immunogenicity. C57BL/6 mice
were immunized twice with 25 µg of SA-4-1BBL s.c. on days 0 and 14, followed by TC1 tumor challenge (1 x 105) s.c. two weeks after the second immunization. Post-tumor
vaccination (50 µg E7-P1 peptide + 25 µg SA-4-1BBL) was administered s.c. 8 days
after tumor challenge. Mice were monitored for a period of 60 days after tumor injection
and measurements were taken twice a week using calipers. Mice were euthanized when
average tumor size ≥ 12 mm or on day 60 post tumor challenge to be considered the
experimental endpoint.
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Figure 15. Anti-SA antibodies generated in vivo upon SA-4-1BBL immunization. ELISA
plates were coated overnight with 50 ng of SA-4-1BBL protein. Next day plates were
washed and incubated with serial dilutions of specified sera for 1.5 hours, after which
goat-anti-mouse secondary antibody conjugated to HRP was added for 1 hour.
Colorimetric reaction was generated using TMB substrate for 30 minutes and plates were
read at 450 nm. Experiment repeated twice with similar pattern detected.
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Figure 16. Subtyping serum ELISA for pre-immunization group on days 21 and 90.
ELISA plates pre-coated with 100 ng of SA-4-1BBL overnight. 1/25 dilution of positive
sera is used the next day to test the IgG1, IgG2a, IgG2b, IgG3, IgM, IgA, and IgG2c
antibody titers. Each data point is indicative of the mean ± SD of duplicate wells.
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Figure 17. SA is immunogenic and drives the proliferation of T cells in vitro. Two naïve
and four immunized C57BL/6 mice with 1 shot of SA-4-1BBL (25 µg s.c.) were used.
Seven days later, spleens were harvested, processed, and cultured in vitro for 48 hours in
the presence or absence of SA stimulation (5 µg/ml). Cultures were pulsed with 3[H]thymidine for additional 16 hours and CPMs were recorded. Each data point represents
the mean ± SEM of triplicate wells.
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Figure 18. Anti-SA antibodies generated in vivo do not help the in vitro proliferative
function of SA-4-1BBL molecule. Sera were collected on day 21 from SA-4-1BBL preimmunized C57BL/6 mice (25µg on days 0 and 14 s.c.). SA-4-1BBL at different doses
(µg/ml) was incubated in vitro with naïve or experimental sera (log10 = 2.8) for 1 hour at
room temperature prior addition to splenocytes stimulated with agonistic anti-CD3 (0.025
µg/ml). Cultures were incubated for 48 hours at 37o / 5% CO2 followed by additional 16
hours with 3[H]-thymidine. Plates were harvested and counts were recorded as CPM.
Each data point represents the mean ± SEM of triplicate wells. Experiment was repeated
twice with same pattern detected.
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Figure 19. Pre-immunization with SA-4-1BBL does not alter the post-tumor vaccination
outcome, but scores 100% survival against TC-1 tumors. Naïve C57BL/6 mice were
immunized twice with 25 µg SA-4-1BBL (days 0 and 14 s.c.). Two weeks later (day 28)
mice were challenged with TC-1 tumors (1 x 105 cells s.c.). On day 36, the preimmunization + post vaccination group received a post-tumor vaccine challenge (50 µg
E7-P1 peptide + 25 µg SA-4-1BBL s.c.). Mice were monitored for 70 days post tumor
injection as shown above. Tumors were measured twice a week using calipers. Mice were
euthanized when average tumor diameters had reached ≥ 12 mm or when experimental
endpoints were met. Experiment repeated twice with mice survival data pooled.
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Figure 20. Time-course pre-immunization studies with 1 shot SA-4-1BBL against TC-1.
C57BL/6 mice were immunized with 1 shot SA-4-1BBL (25 µg s.c.) followed by TC-1
challenge (1 x 105 cells s.c.) 1 day (A), 1 week (B), or 2 weeks (C) after immunization.
Tumor measurements were recorded twice a week using calipers and mice were
euthanized when tumor average diameter ≥ 12 mm. Survival curves were graphed and
log-rank tests were applied between groups using GraphPad software, with p ≤ 0.05 to be
significant.

67

A

100

survival
Percentsurvival
Percent

100

80

80

60

60

40
40
20
20
0

P= 0.0002

0

20
20
4040
Days
inj.inj.
Dayspost
posttumor
tumor

60 60

TC-1
TC-1 (n =8)
22 shots
day
later
TC-1
shotsSA-4-1BBL,
SA-4-1BBL,1 1
day
later
TC-1(n =18)

B
100100

Percent survival
Percent survival

80 80
60 60
40 40
20 20
0 0
0 0

20 20

40 40

60 60

Days
post
tumor
Days
post
tumor
inj.inj.
TC-1
(n =3)
TC-1

(n =5)
2 shots
SA-4-1BBL,
1 week
later
TC-1
2 shots
SA-4-1BBL,
1 week
later
TC-1

Figure 21. Time-course pre-immunization studies with 2 shots SA-4-1BBL against TC-1.
C57BL/6 mice were immunized twice with SA-4-1BBL (25 µg s.c., 2 weeks apart),
followed by TC-1 challenge (1 x 105 cells s.c.) 1 day (A) or 1 week (B), after the 2nd
immunization. Tumor measurements were recorded twice a week using calipers and mice
were euthanized when tumor average diameter ≥ 12 mm. Survival curves were graphed
and log-rank tests were applied between groups using GraphPad software, with p ≤ 0.05
to be significant.
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Figure 22. Time-course pre-immunization studies continuation with 2 shots SA-4-1BBL
against TC-1. C57BL/6 mice were immunized twice with SA-4-1BBL (25 µg s.c., 2
weeks apart), followed by TC-1 challenge (1 x 105 s.c.) 4 weeks and 8 weeks (A) or 12
weeks (B), after the 2nd immunization. Tumor measurements were recorded twice a week
using calipers and mice were euthanized when tumor average diameter ≥ 12 mm.
Survival curves were graphed and log-rank tests were applied between groups using
GraphPad software, with p ≤ 0.05 to be significant.
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Figure 23. SA-4-1BBL establishes significant long-term immune memory against TC-1.
To study TC-1 recurrences, a group of naïve C57BL/6 mice were immunized twice with
SA-4-1BBL (2 weeks apart), followed by 1st TC-1 challenge 2 weeks after the second
immunization. A second group of mice was treated exactly the same with additional
vaccination (50 µg E7-P1 peptide + 25 µg SA-4-1BBL) 8 days after 1st TC-1 challenge.
Mice in both groups were monitored for a period of 60 days after 1st tumor injection. At
the end of day 60, tumor free mice were rechallenged with a 2nd shot of TC-1 and
monitored for additional 80 days. Tumors were measured twice a week using calipers and
mice were euthanized when average tumor diameter ≥ 12 mm. Survival curves were
graphed and Log-rank test was applied to compare groups using GraphPad software, with
p ≤ 0.05 to be significant.
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Figure 24. SA-4-1BBL primarily generates long-term CD4 effector memory.
C57BL/6 mice were immunized twice with SA-4-1BBL (2 weeks apart), followed by
TC-1 challenge 8 weeks after 2nd immunization. Mice were monitored 60 days posttumor challenge, after which tumor free mice were euthanized, spleens and draining
lymph nodes harvested and stained for flow-cytometric phenotyping. For T-effector
memory cells were gated on CD3+CD62LloCD44hi; for T-central memory
CD3+CD62LhiCD44hi; for NK early activation CD3- NK1.1+ CD69+; for NK late
activation CD3- NK1.1+ CD44+.
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Figure 25. SA-4-1BBL rejects tumors in a non-specific fashion. C57BL/6 mice were
immunized twice with SA-4-1BBL (25 µg s.c., 2 weeks apart), followed by LLC (1 x 105
s.c.), or TC-1 (1 x 105 s.c.) challenge 2 weeks after the 2nd immunization. Tumor
measurements were recorded twice a week using calipers and mice were euthanized when
tumor average diameter ≥ 12 mm. Survival curves were graphed and log-rank stats were
calculated between groups using GraphPad software, with p ≤ 0.05 to be significant.
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Figure 26. Anti-SA humoral immune response did not contribute to the SA-4-1-BBLmediated rejection of tumors. Sera collected on Day 27 from SA-4-1BBL immunized
mice (25µg on days 0 and 14 s.c.) were adoptively transferred to naïve C57BL/6 mice
(200 µl i.v.) 24 hours prior TC-1 tumor challenge (1 x 105 s.c.). Tumor diameters were
measured with calipers twice a week. Animals were terminated when average tumor size
≥ 12mm.
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Figure 27. Depletion of NK cells negates SA-4-1BBL’s protective effect. Different
groups of C57BL/6 mice were immunized twice with 25 µg SA-4-1BBL (2 weeks apart),
followed by TC-1 (1 x 105 s.c.) challenge 2 weeks after the 2nd immunization. NK cells
were depleted with anti-NK1.1 Ab clone PK136 (500 µg i.p.) 1 day before SA-4-1BBL
immunizations or 1 day before TC-1 challenge. Tumor measurements were recorded
twice a week using calipers and mice were euthanized when tumor average diameter ≥ 12
mm or when experimental endpoints were reached. Survival curves were graphed and
Log-rank test was applied to compare groups using GraphPad software, with p ≤ 0.05 to
be significant.
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Figure 28. Depletion of CD4 cells but not CD8 cells negates SA-4-1BBL’s protective
effect. Different groups of C57BL/6 mice were immunized twice with 25 µg SA-4-1BBL
(2 weeks apart), followed by TC-1 (1 x 105 s.c.) challenge 2 weeks after the 2nd
immunization. CD4 cells were depleted with anti-CD4 Ab clone GK1.5 (500 µg i.p.),
while CD8 cells were depleted with anti-CD8 Ab clone 53.6.72 (500 µg i.p.) 1 day before
SA-4-1BBL immunizations. Tumor measurements were recorded twice a week using
calipers and mice were euthanized when tumor average diameter ≥ 12 mm or when
experimental endpoints were reached. Survival curves were graphed and Log-rank test
was applied to compare groups using GraphPad software, with p ≤ 0.05 to be significant.
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Figure 29. CD4 cells are required during effector phase after TC-1 challenge. C57BL/6
mice were immunized twice with 25 µg SA-4-1BBL (2 weeks apart), followed by TC-1
(1 x 105 s.c.) challenge 2 weeks after the 2nd immunization. CD4 cells were depleted with
anti-CD4 Ab clone GK1.5 (500 µg i.p.) 1 day before TC-1 injection. Tumor
measurements were recorded twice a week using calipers and mice were euthanized when
tumor average diameter ≥ 12 mm.
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Figure 30. B cells and antibodies are not involved in SA-4-1BBL-mediated tumor
protection. C57BL/6 mice were immunized twice with 25 µg SA-4-1BBL (2 weeks
apart), followed by TC-1 (1 x 105 s.c.) challenge 2 weeks after the 2nd immunization. B
cells were depleted with anti-CD20 Ab clone 5D2 (200 µg i.p.) 1 day before SA-4-1BBL
immunizations. Tumor measurements were recorded twice a week using calipers and
mice were euthanized when tumor average diameter ≥ 12 mm or when experimental
endpoint was reached.
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Figure 31. SA-4-1BBL immunization is ineffective against TC-1 in 4C mice. Either 4C
or wild type C57BL/6 mice were immunized twice with SA-4-1BBL (25 µg s.c.)
followed by TC-1 challenge (1 x 105 s.c.) 2 weeks later from 2nd immunization. Tumor
measurements were recorded twice a week using calipers and mice were euthanized when
tumor average diameter ≥ 12 mm or when experimental endpoints were reached. Survival
curves were graphed and Log-rank test was applied to compare groups using GraphPad
software, with p ≤ 0.05 to be significant.
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Figure 32. 4C splenocytes stimulated with SA have compromised proliferation.
Four 4C and two C57BL/6 mice were immunized with 1 shot of SA-4-1BBL (25 µg s.c.).
Seven days later, spleens were harvested, processed, and cultured in vitro for 48 hours in
the presence or absence of SA stimulation (5 µg/ml). Cultures were pulsed with 3[H]thymidine for additional 16 hours and CPMs were recorded. Stimulation index (SI) =
average cpm on assessment day with stimulation / average cpm on assessment day
without stimulation. Experiment repeated twice with same pattern detected.
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Figure 33. SA-4-1BBL immunization is capable of generating anti-SA antibodies in 4C
mice. 4C or wild type C57BL/6 mice were immunized twice with SA-4-1BBL (2 weeks
apart), and sera were collected 1 week after 2nd immunization (day 21), and at
experimental endpoint when tumors expire. ELISA plates were coated overnight with 50
ng of SA-4-1BBL protein. Next day plates were washed and incubated with serial
dilutions of specified sera for 1.5 hours, after which goat-anti-mouse secondary antibody
conjugated to HRP was added for 1 hour. Colorimetric reaction was generated using
TMB substrate for 30 minutes and plates were read at 450 nm.

80

Absorbance

1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0

IgG1
IgG2a
IgG2b
IgG3
IgM
IgA

IgG2c
(+) Ctrl
B6

4C

4C

naïve 4C

Figure 34. Subtyping ELISA at tumor endpoints for 4C mice pre-immunized twice with
SA-4-1BBL. ELISA plates were pre-coated with 100 ng of SA-4-1BBL overnight. 1/25
dilution of positive sera is used the next day to test the IgG1, IgG2a, IgG2b, IgG3, IgM,
IgA, and IgG2c antibody titers. Each data point is indicative of the mean ± SD of
duplicate wells.
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immunomodulatory molecule. Different groups of C57BL/6 mice were immunized twice
with either SA alone (12.5 µg s.c.), 3H3 alone (100 µg s.c.), SA + 3H3, or SA-4-1BBL
(25 µg s.c.), followed by TC-1 (1 x 105 s.c.) challenge 2 weeks after the 2nd
immunization. Tumor measurements were recorded twice a week using calipers and mice
were euthanized when tumor average diameter ≥ 12 mm or when experimental endpoints
were reached.
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Figure 36. Immunization with 3H3 reduces NK cell percentages in spleen lymphocyte
population. C57BL/6 mice were immunized twice (2 weeks apart) with either (12.5 µg
SA + 100 µg 3H3 n=4) or (25 µg SA-4-1BBL n=4). Three days later, spleens were
harvested, processed, and stained for flow cytometric phenoytping. CD4 T cells were
gated on CD3+CD4+; CD8 T cells were gated on CD3+CD8+; NK cells were gated on
CD3-NK1.1+; and NKT cells were gated on CD3+NK1.1+.
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Figure 37. Immunization with 3H3 reduces NK absolute cell numbers in spleen
lymphocyte population. C57BL/6 mice were immunized twice (2 weeks apart) with either
(12.5 µg SA + 100 µg 3H3 n=4) or (25 µg SA-4-1BBL n=4). Three days later, spleens
were harvested, processed, and stained for flow cytometric phenoytping. CD4 T cells
were gated on CD3+CD4+; CD8 T cells were gated on CD3+CD8+; NK cells were gated
on CD3-NK1.1+; and NKT cells were gated on CD3+NK1.1+. Student’s t-test (two-tailed)
was performed for statistical analysis with *p ≤ 0.05 being significant.
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Figure 38. Immunization with 3H3 reduces NK cell percentages in draining lymph
nodes’ lymphocyte population. C57BL/6 mice were immunized twice (2 weeks apart)
with either (12.5 µg SA + 100 µg 3H3 n=4) or (25 µg SA-4-1BBL n=4). Three days later,
draining lymph nodes were harvested, processed, and stained for flow cytometric
phenoytping. CD4 T cells were gated on CD3+CD4+; CD8 T cells were gated on
CD3+CD8+; NK cells were gated on CD3-NK1.1+; and NKT cells were gated on
CD3+NK1.1+.
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Figure 39. Immunization with SA+3H3 vs. SA-4-1BBL absolute cell numbers profile in
draining lymph nodes. C57BL/6 mice were immunized twice (2 weeks apart) with either
(12.5 µg SA + 100 µg 3H3 n=4) or (25 µg SA-4-1BBL n=4). Three days later, draining
lymph nodes were harvested, processed, and stained for flow cytometric phenoytping.
CD4 T cells were gated on CD3+CD4+; CD8 T cells were gated on CD3+CD8+; NK cells
were gated on CD3-NK1.1+; and NKT cells were gated on CD3+NK1.1+.
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immunized twice with 12.5 µg SA + 100 µg 3H3 Ab. Sera were collected 1 week after
the 2nd immunization and again at tumor endpoints and subjected to anti-SA ELISA.
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